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ABSTRACT
Altered DNA methylation may lead to suboptimal fetal programming, increasing the risk
of adverse pregnancy outcomes such as small for gestational age (SGA); however, few
studies have examined the associations between DNA methylation, prenatal exposures,
and fetal outcomes. Cross-sectional data from a larger, ongoing study were used to
assess the impact of prenatal smoking on gene specific methylation of umbilical cord
blood derived DNA and to investigate the association between gene-specific methylation
and risk of SGA. The association between gene-specific DNA methylation and
birthweight was also assessed. Maternal and infant covariates were abstracted from
medical records, cigarette smoke exposure was determined by measuring cotinine in
umbilical cord blood plasma, and the Illumina Infinium Methylation27 assay was used to
assess CpG site specific methylation. Methylation was represented by a beta value
ranging from 0 to 1. Gene-level methylation was calculated by averaging the methylation
levels over the CpG sites interrogated in that gene. Logistic regression was used to
generate adjusted odds ratios (OR) and 95% confidence intervals (CI) for the
association between SGA and methylation of CYP1A1, HIF1A, GSTT1, and GSTM1 and
the association between cotinine level and hypermethylation of CYP1A1, HIF1A,
GSTT1, and GSTM1. DNA was considered hypermethylated if the beta value was
greater than or equal to the 75th percentile. Univariate and multivariable linear regression
were used to examine the association between birthweight and methylation of the IGF1
and IGF2 gene. The analyses included 90 singleton births. A 0.10 unit increase in
methylation of GSTT1 increased the risk of SGA almost 3-fold (OR=2.69, 95%CI=1.34,
5.43). A 5ng/ml increase in cotinine level increased the risk of hypermethylation of
vi

GSTT1 (OR=1.18, 95%CI=1.02, 1.37). Birthweight did not appear to be impacted by
methylation of IGF2 (β=0.07, 95%CI=-2.91, 3.05), but a one standard deviation increase
in methylation of IGF1 was associated with a 3.63% decrease in birthweight (95%CI=
-6.49, -0.78). No differences in DNA methylation by prenatal vitamin intake were
detected. These findings suggest that DNA methylation plays a critical role in fetal
growth and may mediate the risk of SGA and low birthweight.
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CHAPTER ONE
Introduction and theoretical framework
Specific aims
An increasing number of studies are linking prenatal exposures to adverse birth
outcomes and adult onset disease. For example, heart disease, diabetes, and high
blood pressure have all been associated with suboptimal pregnancy outcomes such as
low birth weight and fetal growth restriction (1-4). Although it is posited that poor fetal
growth is an in utero survival mechanism that enables the fetus to adapt to its
environment, the mechanism underlying these adaptations are still poorly described.
Epigenetic modifications, heritable changes in gene expression that are not
accompanied by changes in genotype, such as DNA methylation, have not been largely
explored as potential mechanisms by which suboptimal uterine conditions leads to poor
fetal growth in humans (5). Nonetheless, experimental evidence has demonstrated that
DNA methylation is critical to normal development of mammals and that abnormal
methylation can result in diseases such as Rett syndrome, neoplasias, and facial
abnormalities (5-7). Accordingly, several genes critical for fetal and postnatal growth are
epigenetically regulated (8-11). Furthermore, DNA methylation appears to be directly
altered by exposures such as cigarette smoke and folic acid (12-15). Although aberrant
DNA methylation has been linked to cigarette smoke, folic acid, and other potential in
utero exposures, less is known about the association between DNA methylation and
birth outcomes. Normal methylation of DNA, a process that is important for regulation of
gene expression and DNA stability, may be disrupted in response to suboptimal uterine
conditions, altering gene expression and subsequently preventing normal growth.
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Given the lack of information about fetal exposures, DNA methylation, and
pregnancy outcomes, this study sought to examine the association between DNA
methylation of specific genes and indicators of fetal growth (small for gestational age
and birthweight). In addition, it examined the impact of prenatal smoking on DNA
methylation. Consequently, the analysis centered on the methylation of genes related to
the metabolism of cigarette smoke carcinogens and genes important for fetal growth.
The central hypothesis of this study is that suboptimal uterine conditions during
pregnancy results in aberrant DNA methylation in umbilical cord blood-derived nucleated
cells, which manifests itself as impaired fetal growth. The hypothesis is tested in a crosssectional study including 92 infants recruited from a larger, on-going study at Tampa
General Hospital (TGH). The study will help elucidate the biological mechanism by which
cigarette smoke exerts its negative effects and, importantly, the role of gene-specific
DNA methylation in mediating fetal growth.
The specific aims of this study include:
1. To investigate the association between small for gestational age (SGA) and
the degree of DNA methylation in genes involved in xenobiotic metabolism
and hypoxic response, specifically hypoxia inducible factor 1, cytochrome
P450, glutathione s-transferase (GST) M1, and GSTT1
2. To determine if there is a dose-response relationship between DNA
methylation of selected xenobiotic metabolism and hypoxic response genes
and risk of SGA
3. To determine whether cigarette smoke exposure is associated with altered
methylation levels in genes involved in metabolism of xenobiotics and
hypoxic response
4. To determine whether suboptimal methylation of the Insulin-like growth factor
(IGF) genes, IGF1 and IGF2 are associated with infant birthweight
2

Fetal growth and birthweight
Birthweight and intrauterine growth restriction (IUGR) are frequently used as
indicators of fetal growth and survival potential. IUGR occurs when infants or fetuses fail
to meet their growth potential and is typically operationalized based on birthweight and
its appropriateness for a given race and gestational age (16, 17). Under this
classification scheme, infants weighing less than the 10th percentile for a given
gestational age, race and gender are considered small for gestational age (SGA), those
above the 90th percentile are large for gestational age (LGA), and the remainder are
appropriate for gestational age (AGA) (16). The percentage of SGA infants born in the
United States ranges from 7.87% for non-Hispanic whites to 15.43% for non-Hispanic
blacks (16). Hispanics have an intermediate rate of 9.30% (16). IUGR can also be
categorized as symmetrical (proportional reductions in weight, length, and head
circumference) or asymmetrical (reductions in weight are markedly higher than
reductions in length or head circumference) (18, 19). Symmetrical growth restriction is
characterized by smaller head dimensions and abdominal size that usually results from
insults that occur early in gestation (birth defects, chromosomal anomalies, smoking,
etc.) when growth occurs by cell division (17, 20). Asymmetrical growth restriction is
marked by normal head dimensions and decreased abdominal size (17, 19).
Asymmetrical growth restriction usually occurs in response to placental factors, diabetes
mellitus, or inadequate nutrition in late pregnancy when cells are increasing in size (17,
20).
On the other hand, birthweight is reflective of fetal growth throughout the
pregnancy. Birthweight is a product of gestational age and fetal growth, thus low
birthweight, a common pregnancy outcome measure, can be attributed to poor fetal
growth or preterm birth. Birthweight is frequently categorized as low birthweight (less
3

than 2500 grams), normal birthweight (2500 grams-4000 grams), or macrosomic (>4000
grams) (21). Birthweight is one of the best predictors of infant mortality, although the
association may not be causal (22). The mean birthweight of singleton infants is 3,325
grams with about 6.2% of singleton infants and 7.9% of all infants being born low
birthweight (21). However, the rates of low birthweight differ by race and ethnicity with
non-Hispanic blacks having the highest rates (13.6%) followed by non-Hispanic whites
(7.0%) and Hispanics (6.2%) (21). Birthweight has a very low heritability, thus it is
thought that environmental factors play a critical role in birthweight determination (23).
The mechanism by which poor fetal growth manifests in response to
environmental factors is unclear, but it may also depend on maternal morbidity and
nutrition (16). Growth is dependent on adequate nutrition, oxygen, and hormones and
growth factors, and suboptimal uterine conditions may impair availability of these factors,
possibly by altering gene expression. Epigenetic modifications are a reversible
mechanism that could account for the alterations in gene expression, and the ability of
some fetuses to circumvent adverse outcomes attributed to adverse uterine
environments.

Exposures associated with fetal growth
Maternal smoking
In the United States, about 21% of reproductive aged women smoke, and about
12% of women continue to smoke during pregnancy (24, 25). An even greater proportion
of women are exposed to environmental tobacco smoke (33%) (26). Numerous large
epidemiologic studies have provided evidence linking prenatal tobacco smoke exposure
to a number of poor birth outcomes, including IUGR, stillbirth, and low birthweight, and
now the relationship between IUGR and prenatal tobacco smoke exposure is presumed
to be causal (27).
4

Reduced fetal growth attributed to prenatal tobacco smoke exposure may be due
to nicotine exposure itself, hypoxia, placental changes, or direct effects of other
chemicals, but the exact mechanism remains unknown. Nicotine, a known
vasoconstrictor, can cross the placenta, exposing the developing fetus to higher nicotine
concentrations than the mother (28, 29). The vasoconstrictive effect of nicotine may
decrease the transfer of nutrients across the placenta and cause hypoxia, impairing
normal processes of fetal growth and development (30). Conversely, animal studies
suggest that carbon monoxide, not nicotine or other chemical exposures is responsible
for the observed decreases in birth weight in fetuses prenatally exposed to tobacco
smoke (31). High carbon monoxide concentrations can cause hypoxia, resulting in
altered trophoblast expression, which are important for placental transfer, hormone
production, and metabolism (32, 33).
Morphological changes in the placentas of smokers have been documented, but
these changes have not been found to be associated with growth restriction (34).
Placentas of smokers have thickened villous membranes, reduced capillary volumes,
and decreased weight, but oxygen diffusion, a factor that may limit growth, does not
seem to be impaired (34-36) Transfer of folate across the placenta may also be
impaired by placental changes, a problem compounded by observations indicating that
smokers have lower serum folate levels than nonsmokers (37). Studies examining
maternal-fetal folate transfer in smokers and nonsmokers have not supported this
hypothesis. Jauniaux et al. reported folate levels inside the first trimester gestational sac
as measured in coelomic fluid did not differ between smokers and nonsmokers, but they
were lower than those found in maternal serum, suggesting that smoking does not
impair placental transfer of folate (37).
Several studies have examined the anthropometric measurements of infants
born to smokers and nonsmokers, noting that tobacco smoke exposure usually causes
5

symmetrical growth restriction (38, 39). Higgins et al. demonstrated that maternal
smoking decreases birth weight, crown-heel length, head circumference, and reduces
brain:body weight ratio (BRR) (40). The same study reported that smoking cessation
before 32 weeks’ gestation eliminated the reductions in birth weight and head
circumference, but deficits in crown-heel length, BRR, and ponderal index remained
(40). Other studies have also linked prenatal smoking to reductions in linear growth,
femur length, head circumference, and abdominal circumference (41-43). Numerous
studies have demonstrated a dose-response inverse relationship between number of
cigarettes smoked and birthweight (42, 44). In addition, fetal growth restriction correlates
with nicotine concentration in fetal blood in a dose-response pattern (45). Both term and
preterm infants are affected by maternal smoking (42).
Maternal smoking is associated with lower concentrations of amino acids in
umbilical cord blood plasma and altered activity of trophoblasts and enzymatic activity
(34, 46). Conversely, studies have shown that there are no differences in triglyceride,
glucose, or albumin concentrations in umbilical cord blood between infants exposed to
cigarette smoke prenatally and their unexposed counterparts (39). When compared to
infants of nonsmokers, those born to smokers have lower insulin-like growth factor and
IGF binding protein 3 in umbilical cord blood (39). In addition, smokers tend to gain less
weight during pregnancy, but this does not explain the decreases in fetal size as an
increase in nutrient intake does not prevent poor fetal growth in infants exposed to
tobacco smoke prenatally (47, 48).

Folate
Folate is a water soluble B vitamin that plays a critical role in human reproduction
(49). It occurs naturally in leafy green vegetables, beans, and liver, but it also exists in
synthetic forms. Folic acid (naturally occurring or synthetic folate) is an important
6

substrate in one carbon metabolism, purine and amino acid synthesis, and methylation
reactions (50-53). Folate is an essential component in reactions proceeding RNA and
DNA synthesis which highlights the significance of folic acid for fetal growth and
development (54).
Food fortification is one method that can help ensure adequate folic acid intake
during the periconceptional period (55, 56). In 1998, the United States (US) Food and
Drug Administration (FDA) began fortifying staple foods, including flour, rice, cereal, and
pasta, with approximately 10% of the recommended daily intake (RDI) of folic acid
(400µg) in an effort to increase folic acid intake (57, 58). Although successful, many
reproductive aged women (aged 15-44) still do not have adequate folate intake (59).
Non-Hispanic white women have the highest intake and the greatest proportion of
women meeting the RDI (30.3%), followed by Mexican-Americans (17.1%) and nonHispanic blacks (9.1%) (59). Dietary supplements including prenatal vitamins and other
vitamins are an important source of folic acid for reproductive aged women. Women who
took supplements containing folic acid were more than 10 times more likely to meet the
RDI than non-users (95%CI=7.1, 14.7) (59).
The success of folate supplementation in decreasing the incidence of neural tube
defects has lead to the investigation of the impact of folate on other fetal outcomes, such
as low birthweight and IUGR (49). A large meta-analysis reported a decreased risk of
low birthweight among infants born to women who used multimicronutrients (OR=0.81,
95%CI=0.73, 0.91) or iron-folic acid supplements (OR=0.83, 95%CI=0.74, 0.93) as
compared to placebo, but there was no difference in risk for SGA (60). Similarly,
Neggers et al found that folate supplementation increased birthweight by 48 grams (61).
In addition, the Generation R Study found that periconceptional folic acid use increases
birthweight by 68 grams (95%CI=37.2, 99.0 grams) (62). The same study also reported
a reduced risk of SGA (OR=0.40, 95%CI=0.22, 0.72) (62). Although some studies
7

reported conflicting results, the importance of folic acid in one carbon metabolism
support the observed associations and additional studies examining the mechanism
underlying the association between folic acid and fetal growth are warranted (50-53, 63).

Biological mechanism linking exposures to birth outcomes and DNA methylation
Epigenetics and DNA methylation
Gene expression is mediated not only by DNA sequence, but also by epigenetic
factors. Epigenetic modifications encompass three main processes: (1) DNA
methylation; (2) histone acetylation; (3) micro-RNA molecules. Epigenetic modifications
such as DNA methylation have been shown to affect disease susceptibility in human and
animal studies as it regulates gene expression (5-7). DNA methylation occurs primarily
at cytosine dinucleotides in the sequence cytosines and guanine (CpG) (64, 65). In most
of the DNA sequence, CpG dinucleotides occur infrequently and a majority (~80%) are
methylated. Alternatively, there are regions of DNA sequence that are very rich in CpG
dinucleotides, termed CpG islands which primarily occur in gene promoter regions.
Interestingly, during active gene transcription (open chromatin structure), CpG islands
are unmethylated (64, 65). About 60% of genes have a CpG island at the 5’ end of the
promoter region which are important for transcriptional regulation (50, 52, 64).
Expression of the promoter associated with a given CpG island is not dependent on
methylation status (i.e. it may not be expressed even though it is not methylated), but
methylation silences the promoter by promoting histone de-acetylation and a closed
chromatin structure (64). Similar activity is seen in X-chromosome inactivation and
imprinting (64). Consequently, disease can often be ascribed to failure to maintain
normal DNA methylation, an epigenetic marker that can be assessed globally or at
specific gene sites.
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In normal fetal development, there is a wave of demethylation after fertilization
that affects all methylated regions except the imprinted loci (66, 67). DNA methylation
patterns are restored as development continues. De novo genome wide methylation
occurs between formation of the blastocyst and gastrulation and then as cells
differentiate, changes in gene-specific methylation occur (66). Imprinting occurs prior to
fertilization and acts to silence either the maternal or paternal allele so that there is
monoallelic expression of imprinted genes (66, 68).Disruption of normal imprinting is
associated with several different syndromes, such as Beckwith Weidemann syndrome
(66, 69).
DNA methylation requires S-adenosylmethionine (SAM), thus nutritional
manipulation of the factors that are involved in the synthesis of SAM could impact DNA
methylation reactions (50-52). However, SAM can be derived from a number of different
dietary factors via different metabolic pathways and disruptions in one factor results in
compensatory changes in other metabolic pathways (50, 51, 70). Figure 1.1 provides a
schematic of some of the substrates and reactions that are involved in DNA methylation.
Complex metabolic pathways involved in the methylation cycle may explain some
authors’ findings. Maloney et al. found that in rats, folate deficient diet intake during
pregnancy did not impact DNA methylation in offspring (71). The authors did observe
metabolic alterations, suggesting that alternative pathways were used to prevent
aberrant methylation. Conversely, studies that looked at folate supplementation as
opposed to folate deficiencies found an increase in DNA methylation, suggesting that
diets deficient in methyl donors, such as folate do not directly influence the methylation
of DNA, but diets rich in methylating factors can restore normal methylation (15, 52).
Other studies have reported hypomethylated DNA in animals fed diets deficient in
choline and methonine (50).
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Maternal supplementation with methyl donors (ie; SAM, folic acid, choline, etc.)
may be able to compensate for the negative effects of adverse intrauterine
environmental exposures that impact DNA methylation. Dolinoy et al (2007)
demonstrated that dietary supplementation of folic acid can prevent CpG site specific
DNA hypomethylation caused by exposure to bisphenol A (BPA), a chemical used in the
manufacturing of certain plastics (14). Restoration of normal methylation patterns
prevents incorrect programming and could preclude subsequent diseases such as
increased body weight, cancer and poor reproductive function (14). Similar results have
been observed in animal studies (15, 72). Lillycrop et al. demonstrated that the offspring
of rats fed protein-restricted diets had hypomethylated DNA in the glucocorticoid
receptor and that supplementation with folic acid could prevent hypomethylation of the
glucocorticoid receptor (15). Therefore, it seems that while high folate diets can prevent
gene specific DNA hypomethylation, low folate diets do not necessary cause DNA
hypomethylation, but it does cause changes in metabolism that may induce alterations in
methylation (71).
Genetic alterations may also impact DNA methylation, such as single nucleotide
polymorphisms (SNPs), especially when SNPs occur within genes that are integrally
linked to the methylation cycle. Methionine synthase reductase, MTHFR, and methionine
synthase are enzymes that have common polymorphisms and the latter two are
influenced by folate deficiencies (51). Associations between these polymorphisms and
diseases such as cancer, birth defects, and cardiovascular disease have been identified.
However, their role in DNA methylation is not entirely clear as it may be modulated by
gene polymorphisms as well as interactions between numerous dietary methyl donors
(51, 73).
Alterations in DNA methylation may be the mechanism by which smoking causes
poor fetal growth as methylation affects gene expression and in turn enzymatic activity
10

important for normal growth. Recent studies have found that several imprinted genes
(genes that are turned on or off permanently via DNA methylation, histone acetylation, or
chromatin modification) play a critical role in placental growth and nutrient transfer (33,
74). Furthermore, maternally expressed genes suppress fetal growth whereas paternally
expressed genes enhance it, thus errors in imprinting can have various affects (68, 74).
Environmental factors, such as smoking can have detrimental effects on methylation and
thus gene imprinting; therefore, a better understanding of the smoking-induced changes
in methylation may further delineate the mechanism by which prenatal smoke exposure
causes IUGR (12, 74). Nonetheless, conflicting evidence has left the exact mechanism
by which smoking exerts its negative effects elusive and to date, smoking cessation is
the only strategy that is known to prevent IUGR and low birthweight.

Epigenetics, smoking, and birth outcomes
While DNA methylation has not been largely studied in relation to smoking during
human pregnancies, it has been investigated in animal studies and studies of cancer.
Reports of smoking-related cancers have demonstrated that tobacco smoke exposure
may impact global and CpG site specific DNA methylation (12, 75). Consistent with
these results, a study of bladder cancer cases suggests that cases had decreased DNA
methylation and that tobacco smoke exposure modified the association between global
DNA methylation and disease (13). The risk of bladder cancer was highest among
current smokers with the highest levels of global DNA methylation (13). Interestingly, the
study noted that global DNA methylation was not associated with genetic polymorphisms
in 1-carbon metabolism such as MTHFR (13). Associations between global DNA
methylation and smoking have been reported in other studies and some noted
correlations between MTHFR and methylation only under conditions of low folate (76).
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Methylation changes in specific genes may mediate fetal response to uterine
conditions ultimately impacting fetal growth. Several genes that are involved in fetal
response to hypoxia and cigarette smoke exposure may also mediate IUGR risk.
Glutathione S-transferases (GST) metabolize environmental pollutants such as
insecticides and carcinogens as well as by-products of oxidative stress (77). GSTM1 is a
major phase 2 enzyme that catalyzes the conversion of phase one metabolites into
glutathione and impaired enzyme activity may alter the response to cigarette smoke
sand other toxicants (77-79). Hypermethylation of GSTM1 or GSTT1 may decrease the
ability to metabolize xenobiotics, prolonging exposure and increase the risk of IUGR.
The cytochrome (CYP) P450 enzymes and GSTT1 are also important for the
metabolism of polyaromatic hydrocarbons (PAHs). Previous studies suggest that altered
expression of genes involved in xenobiotic metabolism may increase the risk of IUGR
(79-81). Further, cancer studies suggest that expression of some of the CYP450
enzymes are down regulated by promoter hypermethylation and abnormal methylation is
associated with some cancers (82). Hypoxia inducible factor 1 (HIF-1) also modulates
gene expression in response to hypoxia and recent evidence indicates that it is mediated
by methylation whereby hypermethylation decreases transcription (83, 84). A summary
of the genes described above is provided in Table 1.1.
Follow-up data from the National Collaborative Perinatal Project examined DNA
methylation in relation to exposures that occurred throughout the life course and
reported an association between prenatal smoke exposure and higher levels of global
DNA methylation in peripheral blood mononuclear cells; however, prenatal smoke
exposure was based on maternal self-report (85). Additional studies are needed to
examine the impact of prenatal smoking on gene-specific methylation as this may impact
gene expression and subsequent fetal growth.
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Epigenetics, folate, and birth outcomes
Both IUGR and low birthweight manifest in response to a number of different
causes, including birth defects and other chromosomal anomalies, multiple gestation,
high altitude, extreme malnutrition, dietary deficiencies, abnormal placenta, or maternal
smoking (17, 86, 87). Most studies examining folic acid and prenatal vitamin use focused
on prevention of birth defects, but DNA methylation is one possible mechanism by which
folic acid may mediate fetal growth.
Folic acid deficiency may prevent normal methylation of epigenetically regulated
genes such as insulin-like growth factor (IGF) 1 and IGF2. In addition to IGF1 and IGF2,
the IGF system also includes insulin, four receptors, and six binding proteins (88). It
regulates fetal and placental growth, promoting cell growth and differentiation and
inhibiting apoptosis (8, 9). Both IGF1 and IGF2 are expressed early in fetal development,
however IGF2 expression exceeds that of IGF1 (88). IGF2 is a paternally imprinted gene
and since expression is regulated by DNA methylation, it may vulnerable to abnormal
methylation during development. Although imprinting can be detected as early as the 8cell stage, after birth, IGF2 expression becomes biallelic in most tissues (88, 89).
Imprinting of IGF2 is regulated by H19, but loss of imprinting of IGF2 can occur
regardless of whether imprinting is disrupted in H19 (90). The importance of methylation
in the expression of IGF2 is underscored by the fact that fetal overgrowth is associated
with imprinting disorders such as Beckwith-Wiedemann syndrome (69, 91). Knockout
studies of IGF1 or IGF2 decreases fetal weight in mice and partial deletion of IGF1 in
humans has similar effects (8, 11). For example, in mice, deletion of IGF2 results in a
fetus that is only 60% of the normal weight (8, 92).
Although epigenetic control of IGF1 has received less attention, animal studies
suggest that IGF1 methylation is altered in intrauterine growth restricted (IUGR) rats and
that hypermethylation decreases IGF1 expression (93). IGF1 and birthweight are
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positively associated and growth restricted infants have low umbilical cord blood levels
of IGF1 compared to their counterparts with normal growth (11, 93, 94). Infant sex and
concentrations of IGF1 and IGF binding protein 3 in umbilical cord blood plasma explain
about 38% of the variability in birthweight after adjusting for gestational age, parity and
maternal height (95). Together, these findings suggest that IGF1 and IGF2 are critical
drivers of fetal growth and that sub-optimal methylation may impair fetal growth (see
Table 1.2).
Although the mechanism by which folic acid impacts fetal growth and
development, its universal methyl-donor status, may enable it to help prevent suboptimal methylation of genes critical for fetal growth. Findings of recent studies such as
that of Steegers-Theunissen et al support this theory as they reported that infants
exposed perinatally to folic acid had higher methylation of the IGF2 DMR (differentially
methylated region) than their unexposed counterparts (10). In addition, a methylation
increase of 1.7% in the IGF2 DMR was associated with increased birthweight (10).
However, it is possible that the time of sampling (about 17 months after delivery)
impacted methylation of IGF2 as IGF2 expression changes after birth (8, 10, 88).
Similarly, prenatal exposure to famine has also been associated with decreased
methylation of IGF2 (96). Few studies have evaluated the impact of methylation of IGF1
or IGF2 on fetal growth in humans and additional studies are needed to explore the
possible associations.

Summary
An increasing number of studies suggest that DNA methylation is a critical
component of fetal development, yet it has not been largely explored as potential
mechanism by which suboptimal uterine conditions leads to poor fetal growth in humans
(5). This study seeks to address the lack of information by examining the relationship
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between DNA methylation of genes involved in xenobiotic metabolism and 1)
biochemically validated prenatal cigarette smoke exposure and 2) risk of SGA. This
information may help elucidate the biological mechanism by which cigarette smoke
exposure causes adverse pregnancy outcomes. In addition, this study examines the
relationships between DNA methylation of IGF1 and IGF2, prenatal vitamin use, and
birthweight. Previous studies have reported conflicting evidence for the association
between birthweight and prenatal vitamin use, but few have examined this association in
relation to a biological mechanism (54, 61, 63). Understanding the mechanisms by which
adverse pregnancy outcomes manifest may lead to enhanced prevention strategies to
reduce the morbidity and mortality associated with adverse pregnancy outcomes such
as SGA and low birthweight.
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Table 1.1 Overview of CYP1A1, HIF1A, GSTM1, and GSTT1 as they relate to fetal
growth, DNA methylation, and response to prenatal cigarette smoke exposure
Gene
CYP1A1

Description/function
 Phase 1 enzyme
 Important for
detoxification and
metabolism of
xenobiotics
 Involved in metabolic
activation of PAHs
from tobacco smoke

HIF1A

 Modulates gene
expression in
response to hypoxia
 Tightly regulated by
oxygen
concentration and
determines the level
of HIF1 activity

GSTT1
and
GSTM1

 2 types of
glutathione Stransferases
 Phase 2 enzymes
involved in
detoxification of
phase 1 metabolites
into compounds that
can be easily
excreted
 Act on a wide range
of epoxides,
hyperperoxides, and
other substrates

Literature overview
 Expression of CYP1A1 associated
with cigarette smoke exposure
 cancer studies suggest that
expression of some of the CYP450
enzymes are down regulated by
promoter hypermethylation and
abnormal methylation is associated
with some cancers
 Placental CYP1A1 upregulated in rat
model of smoking induced IUGR
 Excess PAHs may lead to DNA
adducts
 HIF1a expression is critical for
downstream activation of a number of
genes involved in cell growth and
viability as well as in vascularization,
factors critical for normal fetal growth
 It has been shown that the
expression of HIF1a is epigenetically
regulated and DNA methylation
suppresses expression in some cell
types
 Abnormal methylation of HIF1a may
suppress HIF1a and lead to fetal
growth inhibition.
 Metabolize environmental pollutants
such as insecticides and carcinogens
as well as by-products of oxidative
stress
 Enzymes involved in the metabolism
of cigarette smoke and polyaromatic
hydrocarbons (PAHs), thus impaired
enzymatic activity may alter
detoxification ability
 Loss of expression of these genes
may impair clearance of PAHs or
their metabolic by-products,
interfering with DNA transcription and
replication, or impairment of
trophoblast proliferation, all of which
may increase the risk of IUGR

References
(80-82, 97)

(83, 84, 98,
99)

(77-79)
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Table 1.2 Summary of IGF1 and IGF2
Gene

Description/function

Literature overview

References

IGF1

 Regulates fetal and
placental growth,
promoting cell
growth and
differentiation and
inhibiting apoptosis

(11, 93-95)

IGF2

 Regulates fetal and
placental growth,
promoting cell
growth and
differentiation and
inhibiting apoptosis
 Paternally imprinted
gene
 Expression is
greater than that of
IGF1
 After birth, IGF2
expression
becomes biallelic in
most tissues

 Knockout studies of IGF1
decreases fetal weight in mice
and partial deletion of IGF1 in
humans has similar effects
 Animal studies suggest that IGF1
methylation is altered in
intrauterine growth restricted
(IUGR) rats and that
hypermethylation decreases IGF1
expression
 IGF1 and birthweight are
positively associated and growth
restricted infants have low
umbilical cord blood levels of
IGF1 compared to their
counterparts with normal growth
 Infant sex and concentrations of
IGF1 and IGF binding protein 3 in
umbilical cord blood plasma
explain about 38% of the
variability in birthweight after
adjusting for gestational age,
parity and maternal height
 Knockout studies of IGF2
decreases fetal weight in mice
 Findings of recent studies
reported that infants exposed
perinatally to folic acid had higher
methylation of the IGF2 DMR
(differentially methylated region)
than their unexposed
counterparts.
 A methylation increase of 1.7% in
the IGF2 DMR was associated
with increased birthweight
 Prenatal exposure to famine has
also been associated with
decreased methylation of IGF2

(10, 88, 89,
96)
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Diet

Diet
Methionine

Tetrahydrofolate

S-adenosylmethionine
DNA

DMG

5-10-Methyltetrahydrafolate

Betaine
B12
Methylated DNA

Choline
S-adenosylhomocysteine
Diet

Adenosine
5-Methyltetrahydrafolate
Homocysteine
Diet

Figure 1.1 Schematic of some of the substrates (folate, choline, methionine) and
reactions involved in the methylation of DNA (52, 73)
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CHAPTER TWO
Manuscript 1: The association between fetal growth restriction, cotinine, and DNA
methylation of detoxification and hypoxia related genes

Abstract
Objective: We assessed the impact of prenatal smoking on DNA methylation and the
association between methylation and risk of small for gestational age (SGA).

Methods: Medical record data and biological samples from 90 singleton births were
obtained from an ongoing, cross-sectional study. Cigarette smoke exposure was
determined by measuring cotinine in plasma and CpG site-specific methylation in DNA
extracted from umbilical cord blood was measured with the Illumina Infinium
Methylation27 assay. Gene-level methylation was calculated by averaging the
methylation levels over the CpG sites interrogated in that gene. Maternal and infant
characteristics were compared by SGA status as well as by hypermethylation status
using fisher’s exact test and t-tests as appropriate. Logistic regression was used to
generate adjusted odds ratios (OR) and 95% confidence intervals (CI) for the
association between SGA and methylation of CYP1A1, HIF1A, GSTT1, and GSTM1 and
the association between cotinine level and hypermethylation of the aforementioned
genes.

Results: SGA infants were less likely to have adequate prenatal care and were more
likely to be black and female. Infants with hypermethylation of GSTT1 were more likely
to be black. A 0.10 unit increase in methylation of GSTT1 increased the risk of SGA
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almost 3-fold (OR=2.69, 95%CI=1.34, 5.43) and the association appeared to be dosedependent (p<0.001). The risk of hypermethylation of GSTT1 increased with increasing
cotinine level (5ng/ml increase: OR=1.18, 95%CI=1.02, 1.37; 20ng/ml increase:
OR=1.94, 95%CI=1.06, 3.53).

Conclusion: Methylation appears to play a critical role in fetal response to cigarette
smoke and may influence the risk of SGA.

Introduction
Intrauterine growth restriction (IUGR) is a significant contributor to infant
morbidity and mortality, thus its prevention has important public health implications (17,
100). The spectrum of evidence suggests that the relationship between prenatal
smoking and IUGR is causal (27, 41, 101, 102). However, the mechanism by which
prenatal tobacco smoke exposure causes adverse pregnancy outcomes remains poorly
defined. Studies suggest a number of different modes of action, including
vasoconstriction of the placenta, hypoxia, inhibited amino acid transport, and disrupted
lipid metabolism (30, 103, 104). Although each of these mechanisms is biologically
plausible and has supporting evidence, none has been able to explain why some
fetuses, although exposed to tobacco smoke, are not growth restricted.
Previous studies have identified a number of genes involved in xenobiotic
metabolism and these genes may mediate IUGR risk (79, 105). Glutathione Stransferases (GST) metabolize environmental pollutants such as insecticides and
carcinogens as well as by-products of oxidative stress (77). GSTM1 is one of the
enzymes involved in the metabolism of cigarette smoke and polyaromatic hydrocarbons
(PAHs), thus impaired enzymatic activity may alter detoxification ability (77-79).
Similarly, GSTT1 and the cytochrome (CYP) P450 enzymes are important for the
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metabolism of PAHs and loss of expression of these genes may impair clearance of
PAHs or their metabolic by-products, interfering with DNA transcription and replication,
or impairment of trophoblast proliferation, all of which may increase the risk of IUGR
(79, 80, 106, 107). Further, expression of some of the CYP450 enzymes is mediated by
promoter methylation, with aberrant methylation occurring in some colorectal cancers,
suggesting that changes in methylation may impact disease risk (82). In addition,
hypoxia inducible factor 1 (HIF-1) modulates gene expression in response to hypoxia
and recent evidence indicates that it is silenced by DNA methylation (83, 84).
Studies have shown that DNA methylation can be directly altered by exposure to
cigarette smoke (12, 13). Recent studies have also found that in utero tobacco smoke
exposure changes global and gene-specific methylation profiles in young children (108).
However, the exposure and methylation changes in the aforementioned study were
assessed about 5 to 6 years apart, thus, it is possible that postnatal exposures resulted
in the observed DNA methylation changes (108). Other studies examining detrimental
prenatal exposures also suggest that they may alter DNA methylation. For example,
Pilsner et al found that maternal tibia lead burden was negatively associated with
methylation of umbilical cord genomic DNA (109). Together, these observations suggest
that epigenetic modifications, such as DNA methylation, may be a potential mechanism
by which suboptimal uterine conditions caused by tobacco smoke exposure leads to
IUGR, yet this potential pathway remains insufficiently explored. To examine this
mechanism as a potential pathway, we undertake this study with the following
hypotheses: 1) suboptimal uterine conditions may prevent normal fetal programming
through altered DNA methylation of CYP1A1, HIF1A, GSTM1, and GSTT1, an event that
is subsequently displayed phenotypically as SGA; 2) that there is a dose-response
relationship between gene specific DNA methylation in DNA isolated from mononuclear
cells and risk of SGA whereby infants with the highest methylation levels have the
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highest risk of SGA; and 3) that cigarette smoke exposure is associated with altered
methylation levels in genes involved in metabolism of xenobiotics.

Methods
Study sample and data collection
All study participants in this cross-sectional study were enrolled at Tampa
General Hospital in Tampa, Florida as part of a larger ongoing study examining
lymphocyte subpopulations and prematurity. All pregnant females delivering at Tampa
General Hospital were eligible to participate in the Lymphocyte Study. However, infants
born to women whose prenatal tests indicated that they were HIV positive or Hepatitis B
positive were excluded. Maternal race and ethnicity are not factors for inclusion. For the
present study, infants with birth defects were excluded and only singleton infants were
eligible for inclusion.
De-identified demographic and clinical variables initially collected via medical
record abstraction using standardized forms as part of the parent study were also
obtained. The data elements collected include: gestational age, infant birth weight, infant
sex, presence of infection, delivery complications, presence of birth defects, plurality,
parity, gravidity, prenatal care usage, maternal age, and race.

Umbilical cord blood collection
In addition to medical record data, the Lymphocyte Study also collected umbilical
cord blood samples. The umbilical cord blood samples were collected by venipuncture of
the umbilical cord after delivery of the placenta into tubes containing EDTA and were
processed within 24 hours of collection. Samples were processed at the University of
South Florida. Plasma was removed and stored in 1ml tubes at -80°C for subsequent
cotinine analysis. A ficoll gradient separation was used to isolate the mononuclear layer.
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The amount of cord blood processed varied as the amount collected differed for each
infant. However, it ranged from 0.5ml to 5.5ml. After separation, samples were
suspended in freeze media (fetal bovine serum and 10% DMSO) and stored in liquid
nitrogen. Studies have demonstrated that long term storage of cryopreserved cells does
not impact cell viability or recovery with greater than 80% of nucleated cells recovered
(110).

DNA isolation and DNA methylation assessment
DNA isolation and methylation assessment was done at Wayne State University
Applied Genomics Technology Center. Laboratory personnel were blinded to birth
outcome and other maternal and infant health indicators. DNA was isolated from the
mononuclear fraction of umbilical cord blood using the Qiagen EZ1 DNA tissue kit
according to Lum et al with the exception that PBS (phosphate buffered saline) was
substituted for TE (tris ethylenediaminetetraacetic acid) buffer (111). The mononuclear
fraction is largely comprised of monocytes and lymphocytes, but also contains
hematopoietic stem cells (112). Changes in cells derived from umbilical cord blood
should more directly reflect changes that occurred in relation to suboptimal fetal
environment, leading to IUGR. After extraction, DNA was quantified by loading 3µl of the
DNA suspension in the Trinean Dropsense96.
Bisulfite modification of 0.5 µg of DNA was then done with the EZ-96 DNA
Methylation Kit™ per the manufacturer’s instructions (Zymo Research Corp., USA).
Quantitative, loci-specific methylation of the bisulfite modified DNA was assessed using
the Infinium HumanMethylation27 BeadArray™ (Illumina Inc, San Diego, CA) according
to the manufacturer’s guidelines. The array interrogates 27,578 CpG loci located in more
than 14,000 genes. For each CpG site, two different probes are hybridized with the
bisulfite modified DNA (one against the methylated site and one against the
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unmethylated site). Next, a single-base extension adds one of two possible fluorescent
probes (one for methylated (C) and one for unmethylated (T) alleles). Methylation status
is then represented by a beta value which is calculated from the ratio of fluorescent
signals from methylated to the sum of methylated and unmethylated probes and ranges
from 0 (unmethylated) to 1 (methylated). Background normalization was done according
to the guidelines recommended by Illumina using the GenomeStudio Methylation
module. In short, this method subtracts the average signal of the negative control beadtypes from the probe signals. Normalized beta values were then output and used in
subsequent analyses. Heat maps were generated with the MultiExperiment Viewer (113,
114).
A subset of samples was run in duplicate in order to assess inter-chip variability.
In addition, CpGenome Universal Methylated DNA (Millipore, Temecula, CA) was
bisulfite treated and run with the methylation assay as a positive control. Inter-chip
variability was found to be highly reproducible. Pearson correlation coefficients were
greater than 0.99 for each set of replicates (p<0.0001). In addition to running a positive
control to ensure bisulfite conversion and accuracy of methylation, internal validity was
assessed by examining gender specific methylation of 6 x-linked housekeeping genes
(EFNB1, ELK1, FMR1, G6PD, GPC3, GLA) (115, 116).Overall, methylation of these 6
genes was as expected in that females exhibited hemimethylation and males had very
little methylation at the loci in these genes (p<0.0001 for each gene). Figure 2.1 depicts
the gender specific methylation patterns of these 6 housekeeping genes.

Cotinine assessment
In utero exposure to tobacco smoke (through either passive or active smoking)
was evaluated by measuring cotinine, a metabolite of nicotine, in plasma from umbilical
cord blood. Cotinine has a long half-life and has been previously validated as a
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biomarker of tobacco exposure; therefore, it is the gold standard measure of tobacco
smoke exposure (117-119). A solid phase competitive ELISA was used to assess
cotinine level (Calbiotech, California). All samples were run in duplicate with controls and
standards per the manufacturer’s instructions. In short, 10 µl of plasma sample was
combined with 100 µl of enzyme conjugate, mixed, and incubated for 60 minutes at room
temperature in the dark. Samples were then washed with distilled water and residual
moisture removed. After adding 100 µl of substrate reagent, the samples were incubated
for 30 minutes in the dark and 100 µl of stop solution was added. Absorbance was read
on a plate reader at 450nm.

Statistical analyses
Demographic and clinical variables were classified as follows: parity (nulliparous
or multiparous), and race (black or non-black), prenatal care (adequate or not), labor and
delivery complications (yes or no), and infant sex (male or female). Gestational age was
assessed using both the clinical estimate and date of last menstrual period. Small for
gestational age (SGA) was used as a surrogate indicator of intrauterine growth
restriction. The birth weight percentiles for gestational age created by Alexander et al.
were used to classify infants as SGA (<10th percentile for a given gestational age),
appropriate for gestational age (AGA) (10-90th percentile), or large for gestational age
(LGA) (>90th percentile) (16). Demographic and clinical variables of were compared
between SGA and non-SGA infants (AGA and LGA infants) using fisher’s exact test.
Methylation level was measured at multiple CpG sites for CYP1A1 and HIF1A;
therefore, DNA methylation level for each CpG site was averaged over the gene of
interest. In analyses examining the risk of SGA, DNA methylation was treated as a
continuous variable so that we could assess the impact of several methylation levels on
SGA risk. However, in analyses examining the impact of cigarette smoke exposure on
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level of DNA methylation, DNA methylation was dichotomized as hypermethylated (≥75th
percentile) or unmethylated (<75th percentile). There is currently no consensus on what
level of methylation is indicative of hypermethylation and the 75th percentile was chosen
so that we could adequately differentiate infants with the highest levels of methylation
(120, 121). Although infants are considered exposed to cigarette smoke when the
umbilical cord cotinine level is greater than 1ng/ml, 5 ng/ml and 14 ng/ml increases in
cotinine levels are more indicative of active cigarette smoking (119, 122, 123).
Therefore, these cut-points were used in our analyses examining cigarette smoke
exposure and its association with DNA methylation.
A t-test was used to compare the mean methylation levels of each gene of
interest between SGA and non-SGA infants as well as between infants exposed and
unexposed to cigarette smoke. Logistic regression was used to compute adjusted odds
ratios and 95% confidence intervals for the association between 1) SGA and the
methylation level and 2) methylation level and cigarette smoke exposure. In logistic
regression models, covariates and potential confounders were treated as continuous
variables whenever possible (e.g.cotinine level, maternal age). The contribution of each
differentially methylated gene of interest was assessed independently. Adjusted models
controlled for covariates and potential confounders. Confounders were identified by
comparing the crude and adjusted odds ratios. If the estimate changed by more than
10%, the variable was adjusted for. Dose-response trends were assessed with the
Cochran-Armitage trend test and by generating effect estimates for different levels of
exposure. All tests of hypothesis were two-tailed with a type 1 error rate fixed at 5
percent. SAS version 9.1 (SAS Institute, Cary, NC) was used to perform all analyses.
This study was approved by the University of South Florida Institutional Review Board.

26

Results
After excluding infants with missing data (n=1) and birth defects (n=1), 90 infants
were included in the analysis, of which 11.11% (n=10) were SGA and 88.89% (n=80)
were non-SGA. Table 2.1 presents maternal and infant covariates of SGA and non-SGA
infants. Almost 30% of black infants as opposed to 5.80% of non-black infants were SGA
(p=0.01) When compared to non-SGA infants, SGA infants were more likely to be female
(p=0.01). The cotinine levels of the 11 exposed infants ranged from 1.00ng/ml to
100ng/ml, with an overall mean of 36.43ng/ml. However, the mean cotinine level was
higher among SGA infants (11.80 ng/ml) than non-SGA infants (3.53 ng/ml).
A heat map representing the methylation level for the CpG sites used to
determine the gene-specific methylation level for each sample is depicted in Figure 2.2.
This figure also depicts the positive control DNA for which the sample was almost
completely methylated as expected. Mean methylation of the 4 genes of interest
(CYP1A1, HIF1A, GSTM1, GSTT1) ranged from 0.04 (standard deviation (SD)=0.02) for
HIF1A to 0.10 (SD=0.10) for GSTM1. Mean methylation levels by SGA and smoking
status are presented in Figure 2.3. Visual inspection suggested that there was little to no
difference in methylation level by SGA or smoking status in the CYP1A1 or HIF1A
genes. There appeared to be marginal differences by SGA status in the GSTM1 gene
whereas GSTT1 had the greatest variation in methylation level by for both SGA and
smoking status. Furthermore, when data were compared by methylation level few
differences in maternal and infant characteristics were found (data not shown). However,
of the non-black infants, 20.29% had hypermethylation of GSTT1 whereas of the black
infants 42.86% had hypermethylation of GSTT1 (p=0.05). In addition, of the infants with
complications, 40.74% had hypermethylation of CYP1A1 whereas only 17.46% of infants
without complications had hypermethylation of CYP1A1 (p=0.03).
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In both crude and adjusted logistic regression models, only 1 of the 4 genes was
significantly associated with SGA (Table 2.2). A 0.01 unit increase in methylation of the
GSTT1 gene was associated with an increased risk of SGA (OR=1.10, 95%CI=1.03,
1.18) and the association appeared to be dose dependant. The risk of SGA was most
pronounced among infants with the highest methylation levels of GSTT1 as the risk of
SGA increased with increasing methylation (p<0.001). A 0.05 unit increase in
methylation level was associated with a 22% increased risk of SGA (OR= 1.22,
95%CI=1.06, 1.40), and a 0.10 unit increase in methylation increased the risk of SGA
almost 3-fold (OR=2.69, 95%CI=1.34, 5.43). Increased methylation of the HIF1A gene
appeared to increase the risk of SGA, but the association did not reach statistical
significance in either crude (OR=1.23, 95%CI=0.88, 1.72) or adjusted analyses
(OR=1.59, 95%CI=0.99, 2.56).
Table 2.3 presents the crude and adjusted odds ratios and 95% confidence
intervals for the association between hypermethylation (methylation level greater than or
equal to the 75th percentile) and prenatal smoking. Prenatal smoking as measured by a
5 ng/ml increase in cotinine level was not associated with methylation level of CYP1A1
(OR=0.99, 95%CI=0.85, 1.16), HIF1A (OR=1.08, 95%CI=0.94, 1.24), or GSTM1
(OR=0.94, 95%CI=0.77, 1.16). Similarly, a 14 ng/ml increase in cotinine was not
associated with hypermethylation of the same three genes (CYP1A1, HIF1A, and
GSTM1). However, methylation of GSTT1 was associated with smoking. A 5 ng/ml
increase in cotinine level was associated with an 18% increased risk of hypermethylation
(OR=1.18, 95%CI=1.02, 1.37) and a 14 ng/ml increase in cotinine level was associated
with a 60% increased risk of hypermethylation of GSTT1 (OR=1.59, 95%CI=1.04, 2.42).
Further, the risk of hypermethylation increased with increased cotinine level (p=0.02)
whereby a 20 ng/ml increase in cotinine increased the risk of hypermethylation 2-fold
(OR=1.94, 95%CI=1.06, 3.53) and a 30.0 ng/ml increase in cotinine level was
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associated with a 2.7 fold increased risk of hypermethylation (OR=2.70, 95%CI=1.10,
6.64).

Discussion
This study found that the risk of SGA increased with increasing methylation of the
GSTT1 gene. GSTT1 is important in fetal response to hypoxia and metabolism of
environmental contaminants, thus it is interesting to note that methylation of GSTT1 was
also associated with cigarette smoke exposure.
Few studies have examined the impact of methylation changes in DNA isolated
from umbilical cord blood in relation to fetal outcome or fetal exposures. Two previous
studies reported associations between prenatal tobacco smoke exposure and DNA
methylation. Terry et al found higher levels of global methylation in exposed infants
whereas Breton et al found lower levels of methylation in AluYb8 and higher methylation
8 other genes, though none of the genes were the same as those examined in the
present study (85, 108). Although the study by Terry et al examined global methylation
changes rather than gene-specific changes as presented here, the conclusions were
similar to ours as the authors observed that cigarette smoke exposure increases
methylation in mononuclear cells (85). However, while promoter specific methylation is
associated with transcriptional silencing, global methylation is more representative of
DNA stability and cancer studies indicate that global and CpG site specific methylation
can be quite different (i.e. global hypomethylation and CpG site specific
hypermethylation can coexist) (124).
Although previous studies have identified methylation changes in other genes
associated with IUGR, to our knowledge previous studies have not examined the risk of
SGA in relation to methylation of CYP1A1, HIF1A, GSTT1, or GSTM1 in DNA from
umbilical cord blood-derived nucleated cells (125, 126). Although the association
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between HIF1A and SGA did not reach statistical significance, this study may have been
under-powered to detect an association. Loss of expression of HIF1A may impact the
ability of the developing fetus to respond to hypoxia, thus it is biologically plausible that
methylation of HIF1a may contribute to IUGR risk. HIF1a expression is critical for
downstream activation of a number of genes involved in cell growth and viability as well
as in vascularization, factors critical for normal fetal growth (98). Abnormal methylation
of HIF1a may suppress HIF1a and lead to fetal growth inhibition. Further, it has been
shown that the expression of HIF1a is epigenetically regulated (84). Additional studies
with larger samples sizes are needed to assess the association between methylation of
HIF1A and SGA.
Loss of GSTT1 expression could inhibit detoxification of xenobiotics, increasing
the risk of IUGR. Hypermethylation of GSTT1 may decrease GSTT1 expression, causing
an excess of phase 1 metabolites and increased oxidative stress (127, 128). In turn, this
may lead to the formation of DNA adducts, cellular damage, or altered cell signaling
(127). Although these findings have not yet been replicated, it is conceivable that SGA
manifests in response to adverse uterine conditions via a methylation-mediated
mechanism. The reported association between cigarette smoke exposure and
hypermethylation of GSTT1 further supports the proposed mechanism as
hypermethylation may alter gene expression and allow the accumulation of reactive
oxygen species. Unfortunately, our small sample size prevented us from conducting a
mediation analysis. In addition, our study did not examine the effects of differential
methylation on gene expression, thus additional studies are needed to examine the
impact of methylation changes on gene expression.
This study has several strengths including its use of cotinine to assess cigarette
smoke exposure. Due to societal stigmas associated with maternal smoking during
pregnancy, many women underreport prenatal smoking. Our study overcomes this bias
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by evaluating smoking status with a previously validated biomarker, cotinine, a
metabolite of nicotine (119). It has been successfully measured in umbilical cord blood
by several studies and enables investigators to quantify active and passive exposure to
tobacco smoke (119). Cotinine in umbilical cord blood only represents exposures during
the end of pregnancy, thus the exposure estimates may underestimate the true
exposure level as some women may have quit smoking early in pregnancy. As a result,
our risk estimates may be biased toward the null.
In spite of this study’s strengths, several limitations merit mention. We used a
state-of-the-art, high-throughput methylation array to assess over 27,000 CpG loci. It
has been reported that some CpG sites assessed in this array may fall within
polymorphic sites, which may interfere with our method used to assess methylation (129,
130). The net impact of SNPs on methylation assessments that rely on bisulfite modified
DNA remains unclear, thus the implications of SNPs corresponding to CpG sites
included from the four genes of interest in this study is unknown. However, SNPs are
rare and should not significantly alter study results. We were also unable to control for
gene polymorphisms that may impact the risk of SGA or response to cigarette smoke.
However, several recent studies suggest that polymorphisms in CYP1A1, GSTT1, and
the GSTM1 genes have little or no impact on the association between IUGR and
cigarette smoke exposure, although the literature is somewhat inconsistent (79, 80,
128).
This study relies on derivations from birthweight and gestational age to classify
infants as SGA. Inaccuracies in gestational age measurement can affect how infants are
classified. The clinical estimate can be calculated in several different ways, some of
which are more accurate than others (131). Wingate et al. noted that clinical estimates
and LMP differ in about 50% of the population studied and that the discordance varied
by race and ethnicity, thus there may be some degree of non-differential
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misclassification (131). However, the authors also noted that LMP is an imperfect
measure as well due to recall errors and bleeding early in pregnancy (131). Although
these indicators have faults, they are commonly employed, and in the absence of serial
ultrasound measurements (the gold standard for IUGR classification), they are the best
measure available (17). To ensure that factors associated with extreme prematurity did
not influence our results, we re-ran the analyses excluding infants less than 32 weeks of
gestation. However, the measures of association remained relatively unchanged when
excluding them from the analysis (data not shown). However, it is important to note that
the association between methylation of HIF1A and SGA was significant after excluding
extremely preterm infants (OR=1.62, 95%CI=1.05, 2.60).
Overall, this is the first study to evaluate the methylation status of 4 detoxifying
genes in umbilical cord blood and assess the association with SGA. The associations
between SGA and DNA methylation and smoking and DNA methylation found here
should be investigated further using larger samples. A better understanding of the
impact of methylation change on gene expression and risk of SGA may lead to more
targeted intervention methods. For example, investigation and development of methods
to prevent adverse epigenetic changes may decrease the risk of SGA among infants
born to smokers.
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Table 2.1 Demographic and clinical variables by SGA status
SGA1 (n=10)

Non-SGA (n=80)

n

%

n

%

Nulliparous

5

17.24

24

82.76

Multiparous

5

8.20

56

91.80

p-value

Parity

Race

0.28
0.01

Black
Non-black
Pregnancy complications
Yes
No
Adequate prenatal care

6

28.57

15

71.43

4

5.80

65

94.20

2

0.72
2

7.41

25

92.59

8

12.70

55

87.30

3

0.21

Yes

6

8.45

65

91.55

No

4

21.05

15

78.95

Prenatal vitamin use

1.00

Yes

8

10.96

65

89.04

No

2

11.76

15

88.24

Infant sex

<.01

Male

1

1.96

50

98.04

Female

9

23.08

30

76.92

4

Mean

SD (±)

Mean

SD (±)

Cotinine level (ng/ml)

11.80

25.24

3.53

14.57

0.33

Maternal age

24.90

4.33

28.99

6.58

0.06

Gestational age
38.10
SGA=small for gestational age

1.52

38.18

2.30

0.92

1
2

This includes the presence of diabetes, gestational diabetes, preeclampsia, placental

previa, or hypertension
3

As reported in the medical record

4

SD=standard deviation
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Table 2.2 Risk of SGA associated with a 0.01 unit increase in methylation level
CYP1A13
HIF1A3
GSTM14
GSTT14

OR1
0.87
1.23
0.97
1.08

95%CI2
0.49, 1.55
0.88, 1.72
0.90, 1.05
1.03, 1.13

OR
0.97
1.59
1.01
1.10

95%CI
0.41, 2.29
0.99, 2.56
0.93, 1.09
1.03, 1.18

1

OR=odds ratio

2

CI=confidence interval

3

The adjusted odds ratio controls for gender, smoking, prenatal care, race, maternal

age, and parity
4

The adjusted odds ratio controls for smoking, prenatal care, race, maternal age, and

parity
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Table 2.3 Impact of a 5ng/ml and a 14ng/ml increase in cotinine level on the risk of
hypermethylation
Cotinine level:
CYP1A1
HIF1A
GSTM1
GSTT1
1
OR=odds ratio

5ng/ml
Crude
OR1 95%CI2
0.99 0.85, 1.16
1.05 0.92, 1.20
0.93 0.76, 1.13
1.16 1.00, 1.35

Adjusted
OR3 95%CI
0.99 0.85, 1.16
1.08 0.94, 1.24
0.94 0.77, 1.16
1.18 1.02, 1.37

14 ng/ml
Adjusted
OR
95%CI
0.98
0.63, 1.53
1.25
0.85, 1.84
0.85
0.48, 1.50
1.59
1.04, 2.42

2

CI=confidence interval

3

The adjusted odds ratio controls for maternal age and race
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Methylation Level (Illumina beta value)

0.6

0.5
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0.1

0
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Figure 2.1 Methylation of selected housekeeping genes by gender
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Figure 2.2 Heat map depicting the methylation level of all loci used to calculate the gene-specific methylation level for each sample
and the control DNA
1

The smokers are represented by the darker shade of teal

2

The SGA (small for gestational age) infants are represented by the darker shade of purple
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Figure 2.3 Mean methylation of selected genes by SGA and smoking status
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CHAPTER THREE
Manuscript 2: Is there an association between birthweight and DNA methylation of
IGF1 and IGF2?

Abstract
Objective: To evaluate the association between DNA methylation of IGF1 and IGF2 and
birthweight.

Study Design: Medical record data and biological samples from 92 singletons were
obtained from an ongoing, cross-sectional study. Methylation of DNA extracted from
umbilical cord blood was measured with the Illumina Infinium Methylation27 assay.
Univariate and multivariable linear regression were used to assess the impact of
methylation on percent change in birthweight.

Results: The 90 infants included in the study had a mean birthweight of 3242 grams and
a mean gestational age of 38 weeks. After adjusting for gender, maternal age, parity,
and pregnancy complications, a one standard deviation increase in methylation of IGF1
decreased birthweight by 3.63% (95%CI= -6.49, -0.78). Birthweight was not associated
with increased methylation of IGF2, even after adjusting (β= 0.07, 95%CI= -2.91, 3.05).

Conclusion: Methylation of IGF1, but not IGF2 influences birthweight and may be an
important target for interventions aimed at preventing low birthweight.
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Introduction
Birthweight is an important indicator of fetal growth and is associated with infant
mortality, though the association is unlikely to be causal (22). Low birthweight infants
(less than 2500 grams) have a higher infant mortality rate than their normal weight
counterparts with the infant mortality rate of low birthweight infants being more than 110
times that of infants with normal birthweights (greater than or equal to 2500 grams)
(132). Further, low birthweight infants have a higher risk of several adult-onset diseases.
For example, birthweight is associated with elevated blood pressure, diabetes, and heart
disease later in life (3, 133-135). As a result, it is important to understand the factors that
mediate fetal growth and birthweight and currently the mechanism by which poor fetal
growth manifests in response to environmental factors is unclear, but the insulin like
growth factor (IGF) system appears to play an important role.
The IGF system regulates fetal and placental growth, promoting cell growth and
differentiation and inhibiting apoptosis (8, 9). Although the IGF system includes insulin,
several binding proteins, and multiple receptors, studies suggest that IGF1 and IGF2 are
critical drivers of fetal growth. IGF2 is an imprinted gene that is expressed only from the
paternal allele in most fetal tissues (88). Knockout studies of IGF1 or IGF2 suggest that
it decreases fetal weight in mice and partial deletion of IGF1 in humans has similar
effects (8, 11). However, prenatal IGF2 expression is greater than IGF1 and expression
of IGF2 changes postnatally as it becomes biallelic (8, 88). IGF1 and birthweight are
positively associated and growth restricted infants have low umbilical cord blood levels
of IGF1 compared to their counterparts with normal growth (11, 93, 94). Given this, it is
conceivable that altered expression of IGF1 or IGF2 may be associated with altered fetal
growth.
Epigenetic modifications, namely DNA methylation, are a biologically plausible
mechanism by which environmental and nutritional factors mediate gene expression to
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impact phenotype, including birthweight. Findings of recent studies such as that of
Steegers-Theunissen et al support this theory as they reported that infants exposed
perinatally to folic acid had higher methylation of the IGF2 DMR (differentially methylated
region) than their unexposed counterparts (10). In addition, a methylation increase of
1.7% in the IGF2 DMR was associated with decreased birthweight (10). However, it is
possible that the time of sampling (about 17 months after delivery) impacted methylation
of IGF2 as IGF2 expression changes after birth (8, 10, 88). Similarly, prenatal exposure
to famine has also been associated with decreased methylation of IGF2 (96). Although
epigenetic control of IGF1 has received less attention, animal studies suggest that IGF1
methylation is altered in intrauterine growth restricted (IUGR) rats and that
hypermethylation decreases IGF1 expression (93).
The association of birthweight with lifelong health consequences such as
diabetes and heart disease underscores the importance of understanding the
mechanisms that are the foundation of fetal programming (136, 137). Therefore, we
sought to examine the relationship between birthweight and DNA methylation of IGF1
and IGF2.

Methods
Study sample and data collection
All study participants in this cross-sectional study were enrolled at Tampa
General Hospital in Tampa, Florida as part of a larger ongoing study examining
lymphocyte subpopulations and prematurity. All pregnant females delivering at Tampa
General Hospital were eligible to participate in the Lymphocyte Study. However, infants
born to women whose prenatal tests indicated that they were HIV positive or Hepatitis B
positive were excluded. Maternal race and ethnicity are not factors for inclusion. For the
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present study, infants with birth defects were excluded and only singleton infants were
eligible for inclusion.
De-identified demographic and clinical variables initially collected via medical
record abstraction using standardized forms as part of the parent study were also
obtained. The data elements collected include: gestational age, infant birthweight, infant
sex, presence of infection, delivery complications, presence of birth defects, plurality,
parity, gravidity, prenatal care usage, maternal age, and race.

Umbilical cord blood collection
In addition to medical record data, the Lymphocyte study also collected umbilical
cord blood samples. After delivery of the placenta, umbilical cord blood was collected in
tubes containing EDTA. During cord blood collection, no contact with the mother or
infant occurred. Samples were processed at the University of South Florida within 24
hours of collection. Plasma was removed and stored at -80°C for subsequent cotinine
analysis. The mononuclear layer was isolated using a ficoll gradient. After separation,
samples were suspended in fetal bovine serum and 10% DMSO and stored in liquid
nitrogen. Long term storage of cryopreserved cells does not impact cell viability or
recovery as previous studies have indicated that more than 80% of nucleated cells can
be recovered (110).

DNA isolation and methylation assessment
DNA isolation and methylation assessment was performed at Wayne State
University Applied Genomics Technology Center. Laboratory personnel were blinded to
birth outcome and other maternal and infant health indicators. DNA was isolated from
the mononuclear fraction of umbilical cord blood using the Qiagen EZ1 DNA tissue kit
according to Lum et al with the exception that PBS (phosphate buffered saline) was
42

substituted for TE (tris ethylenediaminetetraacetic acid) buffer (111). The mononuclear
fraction is largely comprised of monocytes and lymphocytes, but also contains
hematopoietic stem cells (112). Methylation changes in DNA from nucleated cells
derived from umbilical cord blood should reflect changes that occurred in relation to the
fetal environment. The Trinean Dropsense96 was used to quantify DNA after extraction.
Bisulfite modified DNA was prepared using the EZ-96 DNA Methylation Kit™
according to the manufacturer’s instructions (Zymo Research Corp., USA). Quantitative,
loci-specific methylation was assessed using the Infinium HumanMethylation27
BeadArray™ (Illumina Inc, San Diego, CA) per the manufacturer’s instructions. The
array interrogates 27,578 loci located in more than 14,000 genes. For each CpG site,
two different probes (one against the methylated site and one against the unmethylated
site) are hybridized with the bisulfite modified DNA. Next, a single-base extension adds
one of two possible fluorescent probes (one for methylated (C) and one for unmethylated
(T) alleles). Methylation status is then represented by a beta value which is calculated
from the ratio of fluorescent signals from methylated to the sum of methylated and
unmethylated probes and ranges from 0 (unmethylated) to 1 (methylated).
Background normalization was done according to the guidelines recommended
by Illumina using the GenomeStudio Methylation module. In short, this method subtracts
the average signal of the negative control bead-types from the probe signals.
Normalized beta values were then output for use in subsequent analyses. Heat maps
were generated with the MultiExperiment Viewer (113, 114). In this study, we are
focused on the methylation status of IGF1 and IGF2; therefore we are only analyzed 6
CpG loci. The nucleotide positions of 5 of the 6 the CpG sites included in this analysis
were located in the CpG islands at chr11: 2,110,452-2,111,041 and chr11:2,115,4272,119,259 and the other was in chr12:101,398,416 in NCBI build 36.1.
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A subset of samples was run in duplicate in order to assess inter-chip variability.
In addition, CpGenome Universal Methylated DNA was used as a positive control
(Millipore, Temecula, CA) and was bisulfite treated and run with the methylation assay.
The positive control was used to ensure bisulfite conversion and accuracy of methylation
measurement. The positive control DNA was almost completely methylated as expected.
Inter-chip variability was assessed and was found to be highly reproducible. Pearson
correlation coefficients were greater than 0.99 for each set of replicates (p<0.0001).
Internal validity was assessed by examining gender specific methylation of 6 x-linked
housekeeping genes (EFNB1, ELK1, FMR1, G6PD, GPC3, GLA) (115, 116). Overall,
methylation of the 6 aforementioned housekeeping genes was as expected in that
females exhibited hemimethylation and males had very little methylation at the loci in
these genes (p<0.0001 for each gene).

Statistical analyses
Demographic and clinical variables were classified as follows: parity (nulliparous
or multiparous), race (black or non-black), prenatal care (adequate or not as recorded in
the medical record), pregnancy complications (yes or no), and infant sex (male or
female). Prenatal vitamin use was dichotomized as yes or no as recorded in the medical
record. Gestational age assessment was based on clinical estimate and the date of last
menstrual period. Tobacco smoke exposure was assessed by measuring cotinine, a
metabolite of nicotine. Gestational age, cotinine level and maternal age were kept as
continuous variables.
Methylation level was measured at one CpG site in the IGF1 gene and multiple
CpG sites in the IGF2 gene. The association between methylation of each gene as well
as each CpG site in the IGF2 gene and infant birthweight was assessed independently.
The association between methylation of the complete IGF2 gene and birthweight was
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assessed by averaging the methylation levels (i.e. the illumina beta values) from each
CpG site across the gene. In order to ease interpretation, Illumina beta values were
converted to z-scores.
Univariate linear regression was used to assess the unadjusted association
between birthweight and DNA methylation of the IGF1 gene, the IGF2 gene, and each
CpG site measured in the IGF2 gene. Multivariable linear regression models were then
constructed to control for primary predictors and potential confounders. The response
variable, birthweight, did not initially meet all the assumptions of linear regression,
therefore birthweight was log transformed to achieve normality. As a result, the reported
effect estimates indicate the percent change in mean birthweight per standard deviation
change in methylation. Confounders were identified by examining the significance of the
covariate upon addition to the unadjusted model. If the p-value was less than 0.05, the
variable was adjusted for. The final models were adjusted for gender, maternal age,
parity, gestational age, and pregnancy complications. All hypothesis tests were twotailed with a type 1 error rate fixed at 5 percent. SAS version 9.1 (SAS Institute, Cary,
NC) was used to perform all analyses. This study was approved by the University of
South Florida Institutional Review Board.

Results
In total, 2 infants were excluded from the analysis because of missing data or
presence of birth defects. The mean birthweight of 90 infants included in the analysis
was 3242.27 grams (Standard Deviation (SD)=654.18 grams) (Table 3.1). The mean
gestational age was 38.17 weeks (SD=2.22). A majority of the women (>80%) used
prenatal vitamins and about 32% were nulliparous.
Methylation was measured at 5 CpG sites in the IGF2 gene. The average
methylation of IGF1, IGF2, and the 5 CpG sites measured in the IGF2 gene are
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presented in Table 3.2. The methylation levels of the CpG sites range from a minimum
of 0.02 to a maximum of 0.52. The overall methylation of the IGF2 gene was 0.24
(SD=0.02), which was slightly lower than that of IGF1 (mean=0.26, SD=0.05). The
methylation level was variable in the IGF2 gene, with CpG site 3 having the lowest
methylation (mean=0.02) and CpG site 2 having the highest level of methylation
(mean=0.52). The heat map in Figure 3.1 depicts the differential methylation of all the
CpG sites for which methylation was measured (includes sites in both IGF1 and IGF2).
In univariate linear regression models, all CpG sites except CpG site 5 suggested
that birthweight decreased with increasing methylation (Table 3.3). Methylation of the
entire IGF2 gene reflected this trend, but the association was not significant (β= -0.62,
95%CI= -5.75, 4.51). Similar results were found for IGF1 (β= -4.05, 95%CI=-9.11, 1.01).
CpG site 3, the site with the lowest mean methylation, was the only site that was
significantly associated with birthweight. Every one standard deviation increase in
methylation was associated with a 5.10% decrease in birthweight. However, after
adjusting for gender, maternal age, parity, gestational age, and pregnancy
complications, the association between birthweight and methylation of CpG site 3 was
no longer significant (β=-1.82, 95%CI= -4.81, 1.16). The association between percent
change in birthweight and one standard deviation increase in methylation of the IGF2
gene remained non-significant (β= 0.07, 95%CI= -2.91, 3.05) as did the associations
between methylation of each of the other CpG sites in the IGF2 gene and birthweight.
After adjusting for confounders, methylation of IGF1 was significantly associated with
birthweight and one standard deviation increase in methylation of IGF1 decreased
birthweight by 3.63% (95%CI= -6.49, -0.78).
Initial assessments indicated that race was not a confounder and therefore it was
not included in the multivariable models. However, we sought to explore this further and
re-ran the analysis including race as well as the other confounders (gender, maternal
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age, parity, gestational age, and pregnancy complications). This did not appreciably alter
the results or the conclusions; therefore race was not included in the final multivariable
model (data not shown).

Discussion
We found that birthweight is associated with methylation of the IGF1 gene, but
not the IGF2 gene. A one standard deviation increase (SD=0.05) in methylation of the
IGF1 gene decreased birthweight by 3.63%. Partial deletion or knockout of IGF1 has
been shown to decrease birthweight in animal models, thus if IGF1 was epigenetically
silenced, similar findings would be expected (8, 11). Although we did not measure IGF1
expression, the methylation site that was assessed was near the transcription start site,
so it is likely that methylation would impact expression, but additional studies are needed
to confirm this.
Previous studies have reported an association between birthweight and folic acid
use and folic acid has been shown to increase gene-specific methylation, thus it is
plausible that a methylation mediated mechanism controls fetal growth (10, 15, 61, 62,
138). Interestingly, prenatal vitamin use, a surrogate indicator of folic acid intake, did not
significantly impact the association between birthweight and methylation of the IGF1 or
IGF2 gene in our regression models. Our small sample size precluded a detailed
investigation of this, but results from analyses examining methylation of IGF1 and IGF2
stratified by prenatal vitamin use were similar to that of the unstratified analysis, but in
most cases did not reach statistical significance (data not shown). Further, 3 women in
this study used high dose folic acid supplements during pregnancy and the mean
methylation levels of these infants did not differ from those of regular prenatal vitamin
users or non-users (data not shown). Nonetheless, our assessment of folic acid intake
was limited to information abstracted from the medical record. We did not have any
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information regarding the trimester that prenatal vitamin use began, the actual dose
received, or dietary folic acid intake, thus these results must be interpreted with caution.
Few previous studies have examined methylation of IGF2 and birthweight. Our
results conflict with those of Steegers-Theunissen et al as they found that increased
methylation of IGF2 decreased birthweight after controlling for periconceptional folic acid
use and gestational age whereas we did not find an association (10). In contrast, a study
by Tabano et al examined methylation in DNA from umbilical cord blood of 60 normal
and 66 IUGR infants (139). Although the study examined a different indicator of fetal
growth (IUGR as opposed to birthweight) the results were similar to those found here in
that infants had similar methylation levels in the IGF2/H19 imprinted region regardless of
whether the infant was growth restricted (139). Other factors may interact with IGF2 to
modulate fetal growth. A study by Ong et al reported a relationship between umbilical
cord blood levels of IGF2 and the IGF2 receptor and that when considered together,
these factors were significantly associated with birthweight (140). Alternatively, one
previous study suggested that methylation of the IGF2 gene is highly conserved, thus it
is possible that more extreme changes in methylation of IGF2 may only be associated
with other outcomes not captured in this study such as Beckwith-Wiedermann syndrome
or miscarriage (139).
Although this unique study provides much needed information on how
methylation of two important genes in the IGF system influence birthweight, several
limitations merit mention. We used a state-of-the-art, high-throughput methylation array
to assess over 27,000 CpG loci. It has been reported that some CpG sites fall within
polymorphic sites and may interfere with our method used to assess methylation (129,
130). The net impact of SNPs on methylation assessments that rely on bisulfite modified
DNA remains unclear, but in this study, there were no known SNPs in 4 of the 6 CpG
sites assessed. The implications of SNPs corresponding to the remaining 2 CpG sites
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included from the two genes of interest in this study is unknown. However, SNPs are
rare and should not significantly alter study results. The small sample size may have
affected study results and prevented some associations from reaching statistical
significance, thus additional studies are needed to examine the role of epigenetics in
fetal growth.
An increasing number of studies are reporting an association between
birthweight and a number of adverse health outcomes such as diabetes and heart
disease (136, 137). A better understanding of the mechanisms that curtail normal fetal
growth, may lead to enhanced strategies that are able to prevent suboptimal fetal growth
and low birthweight. The findings of the current study highlight the need for additional
investigations into the role of epigenetic modifications in the IGF system and their
interactions with folic acid and other methyl donors.
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Table 3.1 Summary of maternal and infant covariates
n

%

69

76.67

21

23.33

71

78.89

19

21.11

Yes

27

30.00

No

63

70.00

Yes

29

32.22

No

61

67.78

Yes

73

81.11

No

17

18.89

Female

39

43.33

Male

51

56.67

Mean

SD (±)3

Cotinine level (ng/ml)

4.45

16.12

Maternal age

28.53

6.48

Gestational age
38.17
As reported in the medical record

2.22

Race
Black
Non-black
Adequate prenatal care

1

Yes
No
Pregnancy Complications

2

Nulliparous

Prenatal vitamin use1

Gender

1
2

This includes the presence of diabetes, gestational diabetes, preeclampsia, placental

previa, or hypertension
3

SD=standard deviation
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Table 3.2 Mean methylation level of the IGF1 gene, the IGF2 gene, and the 5 CpG sites
in the IGF2 gene used to assess the overall methylation level
Mean methylation
IGF1
IGF2
CpG site 1
CpG site 2
CpG site 3
CpG site 4
CpG site 5

0.26
0.24
0.23
0.52
0.02
0.11
0.33

Standard Deviation
(+/-)
0.05
0.02
0.03
0.04
0.01
0.02
0.04
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Table 3.3 Association between birthweight and DNA methylation in the IGF1 and IGF2
genes
Crude
Adjusted
Β1
95%CI3
Β1,2
95%CI
IGF1
-4.05
-9.11, 1.01
-3.63
-6.49, -0.78
IGF2
-0.62
-5.75, 4.51
0.07
-2.91, 3.05
CpG site 1 -0.31
-5.44, 4.83
-0.11
-3.09, 2.86
CpG site 2 -0.24
-5.37, 4.90
0.15
-2.84, 3.14
CpG site 3 -5.10
-10.11, -0.08
-1.82
-4.81, 1.16
CpG site 4 -0.54
-5.67, 4.59
-1.72
-4.67, 1.24
CpG site 5 0.39
-4.74, 5.53
1.25
-1.72, 4.22
1
Percent change in birthweight per standard deviation change in methylation level
2

Adjusted for gender, maternal age, parity, gestational age, and pregnancy

complications
3

CI=confidence interval
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Figure 3.1 Heat map of methylated CpG sites in the IGF1 and IGF2 genes
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CHAPTER FOUR
Conclusions and Recommendations
Although previous studies have found that prenatal exposures such as cigarette
smoke and folic acid influence birthweight and SGA risk, the mechanism underlying
these associations remains unclear (41, 61, 62, 102). One possible mechanism, DNA
methylation, has not yet been fully explored and there is a lack of information about the
influence of prenatal exposures on methylation patterns in DNA isolated from umbilical
cord blood and subsequent pregnancy outcomes. This study used a candiate gene
approach to address this gap by first examining whether methylation of CYP1A1, HIF1A,
GSTM1, or GSTT1 modulates SGA risk and then examining the relationship between
birthweight and methylation of IGF1 and IGF2. The study findings suggest that
methylation may control some of the genes critical for normal fetal growth. Moreover, we
found the risk of SGA increased with increasing methylation of GSTT1, a gene important
for metabolism of cigarette smoke and other xenobiotics (77). Similarly,
hypermethylation of a critical fetal growth gene, IGF1, was associated with birthweight
decrements (8, 11).
We also examined whether abnormal methylation could be the mechanism
underlying previously described associations between prenatal smoking and suboptimal
fetal growth (41, 102). Additional analyses demonstrated that smoking impacts
methylation of GSTT1, but not CYP1A1, GSTM1, or HIF1A. This finding suggests that
abnormal methylation may be caused by in utero exposures and supports our
hypothesis that methylation is the mechanism underlying the association between
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prenatal smoking and SGA. Additional studies are needed to determine if
hypermethylation alters the expression of the GSTT gene.
Although this unique study provides valuable information that helps fill a critical
gap in our knowledge of the mechanisms that influences birthweight and SGA risk, it
seemingly raises more questions than it answers. First, there is a need to further
examine the role of folate in preventing abnormal methylation. Folate appears to have a
beneficial role in pregnancy, decreasing the risk of neural tube defects and preventing
low birthweight, and its role in one carbon metabolism, methylation reactions, and amino
acid synthesis suggests that the mechanism underlying these outcomes may be tied to
abnormal methylation (50, 52, 53). This study found that hypermethylation of IGF1
decreases birthweight, but prenatal vitamin use did not appear to be important in the
association. However, this study used prenatal vitamin use as a surrogate indicator of
folic acid intake and did not consider the duration, dosage, or additional dietary sources
of folic acid which may have masked the true association. Additional studies with more
accurate measures of folic acid intake are needed to determine whether folic acid can
prevent abnormal methylation and associated adverse pregnancy outcomes.
It is also important to acknowledge the possibility that our study results may not
translate to other populations. This study may over-represent high risk pregnancies
since the biological and clinical data was initially collected for a different study. Some of
the discrepancies may be attributed to the design of the parent study as the principle
investigator of that study was based in the neonatal intensive care unit and had greater
access to high risk pregnancies. When several key indicators for our study were
compared to that of the county in which the hospital is located (Hillsborough) and that of
the state, some differences were noted. Our sample had a higher proportion of low
birthweight infants (10.00%) than that of the Hillsborough County (7.61%) or the state
(7.04%) (141). In addition, when compared to the county, the present study had a higher
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proportion of black infants (24.14% versus 21.00%) and a lower proportion of births to
women under 35 years of age (80.00% versus 86.08%) (141).
Perhaps some of the main shortcomings of this study are its sample size and
exploratory design. We were unable to examine how genes in the same system interact
together to produce an adverse outcome. We hope to expand the sample size and
obtain better indicators of folate intake. Although this study used a targeted gene
approach to examine methylation and fetal growth indicators, we also plan to do a more
epigenome wide approach and identify all CpG sites with a high degree of variation in
methylation level. Although this complex, the data gathered for this study are conducive
to such a design as this study obtained data on methylation of more than 27,000 CpG
sites in about 14,000 different genes.
Nonetheless, the mechanisms underlying SGA and low birthweight remain
unclear and additional efforts are needed to increase our knowledge of the role of DNA
methylation in mediating fetal growth as it may lead to the development of methods to
circumvent adverse pregnancy outcomes.
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Participant recruitment and data collection
The Lymphocyte Study
All participants were recruited from a larger, on-going study at Tampa General
Hospital (TGH) which seeks to examine prematurity in relation to lymphocyte
subpopulations in umbilical cord blood samples from infants born at TGH. Participants in
the lymphocyte project are identified at admission to TGH for delivery. The principal
investigator of this study, a neonatology fellow, was based in the neonatal intensive care
unit, thus it is possible that the infants included in this study disproportionately reflect
high risk pregnancies and deliveries. Maternal age, race, and ethnicity are not factors for
inclusion. So as to prevent unnecessary risk, women whose prenatal tests indicated that
they were HIV or hepatitis B positive were not eligible for this study.
Umbilical cord blood collection occurs after delivery of the infant and afterbirth
and involves no direct contact with the mother or infant. After delivery of the placenta, a
transport nurse or physician wiped the umbilical cord with 70% alcohol and betadine as
this is the needle insertion (collection) site. The needle is inserted into the umbilical cord
and held in place while the blood from the cord flows into the attached collection tube
containing EDTA. Approximately 3-5 mL of blood is collected, but the amount collected
depended on the amount available. After collection, the tube was gently inverted to mix
the cord blood with the anticoagulant. The collection tube was then labeled with the date
of collection and the medical record number and placed into a plastic bag. This was then
sealed and sent to the USF lab for storage and preliminary processing. Samples were
processed within 24 hours of collection. At the time of processing, the sample was
assigned a study ID number and the medical record number was transcribed into the
study log so that the medical record information could be abstracted by the principal
investigator at a later date. Thereafter, the samples were labeled only with the study ID
and no personal identifiers.
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Samples were transferred to conical tubes and spun. Then plasma was removed
and stored in 1mL tubes at -80°C for subsequent cotinine analysis. A ficoll gradient
separation was then used to isolate the mononuclear layer. After separation, samples
were suspended in freeze media (fetal bovine serum and 10% DMSO) and stored in
liquid nitrogen.
The principal investigator of the Lymphocyte study abstracted maternal and
infant covariates from electronic medical records (birth record) onto a standardized form
(see Appendix B). This form includes maternal age, the infant’s gestational age, birth
weight, presence of congenital anomalies, type of delivery, placental infection, and
plurality (singleton vs. multiple). The form also collected information on prenatal care.
Although this was initially planned to collected as a yes/no response, the medical record
listed prenatal care as adequate or inadequate if there was prenatal care provided;
therefore this information was also collected on the form. Blood samples are linked to
the mother-infant dyad information with a unique ID.

The current project
In this study, no contact or participation of the mother/infant dyad occurred as all
covariates and blood samples are collected by the Lymphocyte Study. The Lymphocyte
Study provided paper copies of the forms used to abstract medical records as well as
frozen plasma and nucleated cell samples. The paper forms were then entered into an
Access database. After the data was entered into the database, paper forms were
randomly selected compared to the electronic database in order to verify that there were
no transcription errors. The data were also inspected for out of range values. None were
detected. In total, 92 records were entered. One infant’s medical record could not be
located (per the principal investigator’s note) and one infant had a birth defect, thus
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these 2 infants were excluded from the analysis as they did not meet the study criteria.
Although the Lymphocyte Study included some multiple births, the medical record
information for these infants was not provided. Therefore, the total number of infants in
the present study is less than that of the parent study.
Cotinine assays were done at the University of South Florida using a solid phase
competitive ELISA (Calbiotech, California). All cotinine assays were performed by the
principal investigator in duplicate per the manufacturer’s instructions. Absorbance was
read on a Biotek Synergy 2 plate reader using Gen5 software.
DNA isolation and methylation assessment was done at Wayne State University
Applied Genomics Technology Center using 300ul to 500ul of cell suspension. The
amount of DNA obtained from the cells varied greatly as the number of nucleated cells
per microliter of freeze media varied. The variation in the number of cells in the freeze
media is attributed to the fact that the number of cells collected was not quantified for a
majority of the samples prior to aliquoting and freezing. The concentration of DNA
extracted from each sample is presented in Table A.1.
The Infinium HumanMethylation27 BeadArray™ (Illumina Inc, San Diego, CA) is
designed so that 24 samples can be run per chip, therefore, 4 chips were required to run
the 92 samples. Samples were run in duplicate to assess inter-chip variability, so 1 set of
duplicates was run on chips 1 and 2, another on chips 2 and 3, and the last one on chips
3 and 4. The 3 samples run in duplicate were: JS020, JS052, and JS079. The samples
were randomly selected from those samples with enough DNA for more than one
methylation assay.
The methylation assay requires bisulfite modified DNA which was prepared using
the EZ-96 DNA Methylation Kit™ according to the manufacturer’s instructions (Zymo
Research Corp., USA). The bisulfite modification step converts unmethylated cytosines
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to uracil whereas methylated cytosines are protected by the covalently bound methyl
group. The DNA is then amplified and applied to a chip. Quantitative, loci-specific
methylation is assessed using the Infinium HumanMethylation27 BeadArray™ (Illumina
Inc, San Diego, CA). The array interrogates 27,578 loci located in more than 14,000
genes. Two different probes (one against the methylated site and one against the
unmethylated site) are hybridized with the bisulfite modified DNA. Next, a single-base
extension adds one of two possible fluorescent probes (one for methylated (C) and one
for unmethylated (T) alleles). The samples are stained and scanned. Methylation status
is then represented by a beta value which is calculated from the ratio of fluorescent
signals from methylated to the sum of methylated and unmethylated probes and ranges
from 0 (unmethylated) to 1 (methylated).
Background normalization was done according to the guidelines recommended
by Illumina using the GenomeStudio Methylation module. This method subtracts the
average signal of the negative control bead-types from the probe signals. The median
absolute deviation method is used to remove outliers. Step by step instructions for
normalizing the data are detailed in the Illumina user manual. Normalized beta values
were then output into text files and used in subsequent analyses. Heat maps were
generated with the MultiExperiment Viewer (113, 114).

Assessment of methylation analysis success
First the methylation level of the control DNA was examined in order to ensure bisulfite
conversion. Since this DNA was almost completely methylated as expected, I then
assessed internal validity by examining gender specific methylation of 6 x-linked
housekeeping genes (EFNB1, ELK1, FMR1, G6PD, GPC3, GLA) (115, 116). Overall,
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methylation of these 6 genes was as expected in that females exhibited hemimethylation
and males had very little methylation at the loci in these genes (p<0.0001 for each
gene). The mean methylation level of each of the housekeeping genes by gender is
presented in Table A.2. The Illumina Infinium assay required 4 chips, thus a subset of
samples were run in duplicate to assess inter-chip variability. Pearson correlation
coefficients were greater than 0.99 for each set of replicates (p<0.0001). Table A.3
presents the correlation coefficients and p-values for each set of duplicates.

Analysis of manuscript 1
SGA and methylation level
A total of 90 infants were included in this analysis. Maternal and infant
characteristics of SGA and non-SGA infants were compared using fisher’s exact test and
t-tests as appropriate. SGA was defined as having a birthweight that is less than the
10th percentile for a given gestational age based on the birthweight percentiles for
gestational age created by Alexander et al. A t-test was used to compare the mean
methylation levels of each gene of interest between SGA and non-SGA infants. Logistic
regression was used to compute adjusted odds ratios and 95% confidence intervals for
the association between SGA and the methylation level of each gene. The beta values
obtained from the methylation assay were treated as continuous variables. The
methylation of the CYP1A1 gene was determined by averaging the beta-values of 4 CpG
sites whereas the methylation level of the HIF1A gene was determined by averaging the
beta values of 2 CpG sites. The methylation of GSTM1 and the GSTT1 genes were each
based on the methylation level of one CpG site. Table A.4 presents the mean, standard
deviation, and the minimum and maximum beta values of each CpG site assessed.
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Adjusted models controlled for covariates and potential confounders. Variables used in
this analysis were classified as follows:

1. Gender: Male or female
2. Parity: nulliparous or multiparous
3. Cigarette smoke exposure: Two indicators of cigarette smoke exposure were
considered. The first (smoker) was a dichotomous variable (yes or no). Smokers
included everyone with a cotinine level ≥1.0. Cigarette smoke exposure was also
evaluated as a continuous variable (cotinine) by including the cotinine
measurement in the model.
4. Prenatal vitamin use: Yes or no as indicated in the medical record.
5. Pregnancy complications: yes or no. Pregnancy complications included the
presence of diabetes, gestational diabetes, preeclampsia, placental previa, or
hypertension.
6. Maternal age: This was left as a continuous variable.
7. Prenatal care: This was originally classified as adequate, inadequate, or none.
However, due to the small sample size, this was reclassified as adequate or not.
8. Race: Race was originally classified as black, white, Hispanic, or other. However,
the small sample size required that some of these categories be combined.
Therefore it was reclassified as black or non-black. In addition, we examined
race classified as black, white, or other.

In this analysis, SGA was the main outcome of interest and DNA methylation of each
gene was the primary predictor. Although DNA methylation is a possible mediator in the
SGA-smoking relationship, we were unable to assess this because the study sample
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had few smoke exposed SGA infants. Gender, parity, race, prenatal vitamin use,
pregnancy complications, prenatal care, maternal age, and smoking were examined as
potential confounders. Confounders were identified by comparing the crude and
adjusted odds ratios. The models for the crude analysis are:

logit {Pr(SGA=1|X)}=β0+β1(CYP1A1)

logit {Pr(SGA=1|X)}=β0+β1(HIF1A)

logit {Pr(SGA=1|X)}=β0+β1(GSTM1)

logit {Pr(SGA=1|X)}=β0+β1(GSTT1)

Potential confounders were added to the models one at a time and if the estimate
changed by more than 10%, the variable was adjusted for. Table A.5 below summarizes
the models and confounders assessed as well as the different classifications that were
considered.
The final models used race as a dichotomous variable (black or non-black) and
kept variables continuous whenever possible (maternal age and cotinine level as the
indicator of cigarette smoke exposure). The final models are:

logit {Pr(SGA=1|X)}=β0+β1(CYP1A1)+β2(gender)+β3(cotinine)+β4(prenatal
care)+β5(race)+ β6(maternal age)+β7(parity)
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logit {Pr(SGA=1|X)}=β0+β1(HIF1A)+β2(gender)+β3(cotinine)+β4(prenatal care)+β5(race)+
β6(maternal age)+β7(parity)

logit {Pr(SGA=1|X)}=β0+β1(GSTM1)+β2(cotinine)+β3(prenatal care)+β4(race)+
β5(maternal age)+β6(parity)

logit {Pr(SGA=1|X)}=β0+β1(GSTT1)+β2(cotinine)+β3(prenatal care)+β4(race)+
β5(maternal age)+β6(parity)

The small sample size precluded the use of additional variable classifications.
Both crude and adjusted estimates are reported in the final manuscript and the adjusted
estimates controlled for confounders and covariates that previous authors found to be
strongly associated with DNA methylation or SGA risk. Gender was the only confounder
identified and it was included in models examining methylation of CYP1A1 and HIF1A. In
addition, models were adjusted for smoking, prenatal care, race, maternal age, and
parity. These variables were selected because smoking, race, and age have all be found
to be associated with DNA methylation. Parity is frequently tied to maternal age and it as
well as each of the other covariates has been reported to be associated with SGA risk. A
summary of the parameter estimates and model fit statistics are presented in Table A.6.
Dose-response trends were assessed with the Cochran-Armitage trend test and by
generating effect estimates for different levels of exposure. This statistic is the same as
the score test statistics in the testing global null hypothesis section of the proc logistic
output.
In sub-analyses related to the discussion portion of the manuscript, the impact of
gender on the results was assessed by excluding male infants. This exclusion was done
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because there was only 1 SGA male and gender was identified as a confounder in some
of the analyses. The results were very similar. As in our original analysis, only
methylation of GSTT1 was associated with SGA risk in both crude (OR=1.11,
95%CI=1.04, 1.20) and adjusted analyses (OR=1.13, 95%CI=1.01, 1.26). Similarly,
excluding extremely preterm infants (<32 weeks of gestation) did not markedly alter the
interpretation of the results. The adjusted odds ratios for a 0.01 increase in methylation
were similar for CYP1A1 (OR=1.20, 95%CI=0.48, 3.03), HIF1A (OR=1.62, 95%CI=1.05,
2.60), GSTM1 (OR=1.00, 95%CI=0.92, 1.09), or GSTT1 (OR=1.10, 95%CI=1.03, 1.18).
However, it is important to note that the association between methylation of HIF1A and
SGA was significant after excluding extremely preterm infants.

Hypermethylation and cotinine level
For this analysis, the impact of cigarette smoke exposure on DNA methylation
was assessed using the same 90 infants in the previous analysis. In order to assess this,
the outcome, DNA methylation, was dichotomized. The current literature on DNA
methylation classified hypermethylation in different ways and there does not appear to
be a consensus on what level of methylation is indicative of hypermethylation. For
example, Dietrich et al used the median and Zhu et al used greater than the 90th
percentile (120, 121). Although I considered using a cut-point at the mean, it was
thought that this may not adequately differentiate infants with much higher levels of
methylation. Therefore, infants with methylation level at or above the 75th percentile were
compared to those with a methylation level falling below the 75th percentile. The cut
points (based on Illumina beta values) used to differentiate between hypermethylation
and normal methylation are: 0.0823591 (CYP1A1), 0.0409117 (HIF1A), 0.0569107
(GSTT1), and 0.1739638 (GSTM1).
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Although a cotinine level greater than 1ng/ml is indicative of cigarette smoke
exposure, we left cotinine as a continuous variable so that we could look at the impact of
several different levels of exposure in relation to methylation. Maternal and infant
characteristics of infants with hypermethylation were compared to those with normal
methylation using fisher’s exact test and t-tests as appropriate. Each gene was
considered separately. Confounders and covariates considered for inclusion in the
adjusted models were classified as follows:

1. Gender: Male or female
2. Parity: nulliparous or multiparous
3. Prenatal vitamin use: Yes or no as indicated in the medical record.
4. Pregnancy complications: yes or no. Pregnancy complications included the
presence of diabetes, gestational diabetes, preeclampsia, placental previa, or
hypertension.
5. Maternal age: This was left as a continuous variable.
6. Prenatal care: This was originally classified as adequate, inadequate, or none.
However, due to the small sample size, this was reclassified as adequate or not.
7. Race: Race was originally classified as black, white, Hispanic, or other. However,
the small sample size required that some of these categories be combined;
therefore it was reclassified as black or non-black. In addition, we examined race
classified as black, white, or other.
8. Gestational age: This was left as a continuous variable.

Logistic regression was used to compute crude and adjusted odds ratios and 95%
confidence intervals for the risk of hypermethylation of each gene for a given cotinine
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level. The main outcome of interest was hypermethylation of each gene and cigarette
smoke exposure acted as the primary predictor in this analysis. The crude models that
were examined in this analysis are:

logit{Pr(Hypermethylation of CYP1A1 =1|X)}=β0+β1(cotinine)

logit{Pr(Hypermethylation of HIF1A =1|X)}=β0+β1(cotinine)

logit{Pr(Hypermethylation of GSTM1 =1|X)}=β0+β1(cotinine)

logit{Pr(Hypermethylation of GSTT1 =1|X)}=β0+β1(cotinine)

Gender, parity, prenatal vitamin use, pregnancy complications, maternal age, prenatal
care, race, and gestational age were examined as potential confounders. Adjusted
models controlled for covariates and potential confounders. Confounders were identified
by comparing the crude and adjusted odds ratios. If the estimate changed by more than
10%, the variable was adjusted for. Table A.7 below summarizes the models and
confounders assessed as well as the different variable classifications that were
considered. None of the variables that we assessed were considered confounders under
the definition described above. However, the adjusted odds ratios control for maternal
age and race because these are important variables in continued smoking during
pregnancy and have been associated with DNA methylation. In the final model cotinine
was kept as a continuous variable, race was dichotomized (black or non-black) and
maternal age was kept as a continuous variable. Crude and adjusted odds ratios are
reported in the final manuscript.
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The final adjusted models are:

logit{Pr(Hypermethylation of CYP1A1 =1|X)}=β0+β1(cotinine)+β2(race)+β3(maternal age)

logit{Pr(Hypermethylation of HIF1A =1|X)}=β0+β1(cotinine)+β2(race)+β3(maternal age)

logit{Pr(Hypermethylation of GSTM1 =1|X)}=β0+β1(cotinine)+β2(race)+β3(maternal age)

logit{Pr(Hypermethylation of GSTT1 =1|X)}=β0+β1(cotinine)+β2(race)+β3(maternal age)

A summary of the parameter estimates and fit statistics for the crude and adjusted
models are presented in Table A.8. The risk of hypermethylation was examined for a
5ng/ml increase in cotinine level and a 14ng/ml increase, levels which were selected
based on previous research. Infants are generally considered to be exposed to cotinine
if the cord blood cotinine level is greater than 1 ng/ml (119, 122, 123). Nafstad et al
found that 14ng/ml differentiates active and passive smokers well, but it does not
capture occasional smokers (123). Further, the study found that an increase in one
cigarette per day increased cotinine levels by almost 5ng/ml (4.4 ng/ml; 95% CI: 1.1-7.6)
(123). Dose-response trends were assessed with the Cochran-Armitage trend test and
by generating effect estimates for different levels of exposure. This statistic is the same
as the score test statistics in the testing global null hypothesis section of the proc logistic
output.
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Analysis of manuscript 2
For this manuscript we sought to examine the association between birthweight
and methylation of the IGF2 gene, each CpG site assessed in the IGF2 gene, and the
IGF1 gene. Birthweight, the dependant variable, was treated as continuous. Methylation
of the IGF1 gene was based on the methylation level of one CpG site in that gene
whereas the methylation level of the IGF2 gene was determined by averaging the
methylation of 5 CpG sites in the IGF2 gene. Covariates were kept as continuous
variables whenever possible. Variables considered for inclusion in the adjusted models
were classified as follows:

1. Gender: Male or female
2. Parity: nulliparous or multiparous
3. Prenatal vitamin use: Yes or no as indicated in the medical record.
4. Pregnancy complications: yes or no. Pregnancy complications included the
presence of diabetes, gestational diabetes, preeclampsia, placental previa, or
hypertension.
5. Maternal age: This was kept as a continuous variable.
6. Prenatal care: This was originally classified as adequate, inadequate, or none.
However, due to the small sample size, this was reclassified as adequate or not.
7. Race: Race was originally classified as black, white, Hispanic, or other. However,
the small sample size required that some of these categories be combined;
therefore it was reclassified as black or non-black. In addition, we examined race
classified as black, white, or other.
8. Gestational age: This was kept as a continuous variable.
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9. Preterm birth: yes or no. Infants were considered preterm if they were less than
37 weeks of gestation.
10. Cigarette smoke exposure: Two indicators of cigarette smoke exposure were
considered. The first (smoker) was a dichotomous variable (yes or no). Smokers
included everyone with a cotinine level ≥1.0. Cigarette smoke exposure was also
evaluated as a continuous variable (cotinine) by including the cotinine
measurement in the model.

In order to ease interpretation and ensure linearity between the outcome and
methylation level, Illumina beta values were converted to z-scores. The z-scores were
then used in the regression models. The validity of this transformation was assessed by
plotting birthweight verses the transformed methylation values. The plots for IGF1 and
IGF2 are depicted in Figures A.1 and A.2.
First, univariate linear regression was used to assess the crude association
between birthweight (outcome) and DNA methylation of the IGF1 and IGF2 genes
(primary predictors). The crude models assessed were:

E (Birthweight|X) = β0+β1(IGF1)

E (Birthweight|X) = β0+β1(IGF2)

I then checked to ensure that the normality assumption was not violated. Residuals were
generated for the models and then plotted verses the predicted values. According to the
Shapiro-Wilk statistic, the data were not normal for IGF2 (p= 0.0306), but IGF1 appeared
to be normal (p= 0.0742). As a result, the outcome, birthweight, was log transformed.
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This resulted in normally distributed data for IGF1 (p= 0.6260) and IGF2 (p=0.5548)
based on the Shapiro-Wilk statistic. As a result of these transformations, the reported
effect estimates indicate the percent change in the average birthweight (100*parameter
estimate) per one standard deviation change in methylation. Crude models were then rerun using the transformed variable.

Gender, parity, prenatal vitamin use, cigarette smoke exposure, pregnancy
complications, maternal age, prenatal care, race, and gestational age were examined as
potential confounders. In addition, prenatal vitamin use was assessed as a possible
moderator. I then identified potential confounders by adding each covariate to the
unadjusted model. Each covariate was assessed independently and if the p-value
associated with that variable was less than 0.05, the variable was adjusted for. A
summary of the confounders assessed and their associated p-values are presented in
Table A.9. Multivariable linear regression models were then constructed to control for
potential confounders. The final models were adjusted for gender, maternal age, parity,
gestational age, and pregnancy complications.

E {(log(Birthweight))|X} = β0+β1(IGF1)+β2(gender)+β3(parity)+β4(gestational
age)+β5(complication)

E {(log(Birthweight))|X} = β0+β1(IGF2)+β2(gender)+β3(parity)+β4(gestational age)
+β5(complication)

E {(log(Birthweight))|X} = β0+β1(IGF2, CPG site1)+β2(gender)+β3(parity)+β4(gestational
age) +β5(complication)
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E {(log(Birthweight))|X} = β0+β1(IGF2, CPG site 2)+β2(gender)+β3(parity)+β4(gestational
age) +β5(complication)

E {(log(Birthweight))|X} = β0+β1(IGF2, CPG site 3)+β2(gender)+β3(parity)+β4(gestational
age) +β5(complication)

E {(log(Birthweight))|X} = β0+β1(IGF2, CPG site 4)+β2(gender)+β3(parity)+β4(gestational
age) +β5(complication)

E {(log(Birthweight))|X} = β0+β1(IGF2, CPG site 5)+β2(gender)+β3(parity)+β4(gestational
age) +β5(complication)

A summary of the parameter estimates and fit statistics for the crude and final models
are presented in Table A.10. Initial assessments indicated that race was not a
confounder and therefore it was not included in the multivariable models. However, I
sought to explore this further and re-ran the analysis including race as well as the other
confounders (gender, maternal age, parity, gestational age, and pregnancy
complications) in the model. This did not appreciably alter the results or the conclusions;
therefore race was not included in the final multivariable model (Table A.11).
Interestingly, prenatal vitamin use, a surrogate indicator of folic acid intake, did
not significantly impact the association between birthweight and methylation of the IGF1
or IGF2 gene in our regression models. Our small sample size precluded a detailed
investigation of this, but we did stratify the data by prenatal vitamin use to do an
exploratory examination of the data. Stratified analysis suggested that the associations
between methylation of IGF2 and birthweight differed by maternal prenatal vitamin use,
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but the associations were not significant even after adjusting for confounders. Among
infants exposed to prenatal vitamins, one standard deviation increase in methylation of
IGF2 was associated with a non-significant 0.78% decrease in birthweight (95%CI-4.17,
2.61). On the other hand, among infants born to women who did not use prenatal
vitamins, a one standard deviation increase in methylation of IGF2 was associated with
a 3.72% increase in birthweight (95%CI= -5.32, 12.76). Results from analyses examining
IGF1 stratified by prenatal vitamin were similar to that of the unstratified analysis. Among
prenatal vitamin users, a one standard deviation increase in methylation of IGF1 was
associated with a 4.21% decrease in birthweight (95%CI= -7.44, -0.98). Comparable
results were found for women who did not use prenatal vitamins, though they were not
statistically significant (β= -3.71, 95%CI= -11.07, 3.64). In an attempt to increase power
in the examination of prenatal vitamin use as a moderator of the DNA hypermethylation–
birthweight association, prenatal vitamin use and an interaction term were added to the
final model for IGF1 and then IGF2. In both cases, the interaction terms were nonsignificant [(IGF1=-3.93, 95%CI=-12.72, 4.87); (IGF2=-7.32, 95%CI=-16.95, 2.31)].
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Table A.1 Concentration (ng/µl) of DNA extracted from each sample of umbilical cord
blood derived nucleated cells

Sample ID

Concentration
(ng/µl)

Sample ID
(continued)

Concentration
(ng/µl)

Sample ID
(continued)

Concentration
(ng/µl)

207

36.69

JS032

77.02

JS066

96.78

210

42.95

JS033

99.86

JS067

113.88

213

41.98

JS034

0.41

JS068

21.27

214

42.2

JS035

5.86

JS069

112.04

215

50.17

JS036

19.11

JS070

3.52

216

53.87

JS037

19.85

JS071

8.1

JS007

74.6

JS040

95.79

JS074

9.06

JS008

46.78

JS041

7.8

JS075

65.26

JS009

82.7

JS042

9.59

JS076

3.14

JS010

119.36

JS043

94.05

JS077

81.52

JS011

21.06

JS044

16.68

JS078

1.58

JS012

14.39

JS045

82.07

JS079

30.85

JS013

13.54

JS046

11.1

JS080

1.47

JS014

12.92

JS047

9.12

JS081

6.66

JS015

16.75

JS048

53.25

JS082

53.71

JS016

8.19

JS050

11.53

JS083

69.04

JS017

66.31

JS051

20.94

JS084

126.35

JS018

12.75

JS052

26.69

JS085

43.28

JS019

31.16

JS053

10.42

JS086

3.37

JS020

92.52

JS054

85.04

JS087

85.1

JS021

98.21

JS055

3.79

JS088

74.16

JS022

16.33

JS056

142.1

JS089

66.55

JS023

24.59

JS057

120.47

JS090

88.74

JS024

83.12

JS058

102.84

JS091

154.26

JS025

17.75

JS059

19.36

JS092

118.69

JS026

39

JS060

40.06

JS093

38.98

JS027

149.81

JS061

4.33

JS094

3.5

JS028

118.61

JS062

45.33

JS099

140.47

JS029

36.54

JS063

114.35

JS100

85.14

JS030

38.49

JS064

79.45

JS101

107.97

JS031

8.58

JS065

165.39

blank__93

0
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Table A.2 Distribution of the mean methylation level of each housekeeping gene by
gender

Gene
EFNB1
GLA
FMR1
GPC3
ELK1
G6PD

Mean Methylation Level
Male
Female
0.05
0.39
0.06
0.25
0.19
0.45
0.03
0.57
0.05
0.55
0.05
0.33
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Table A.3 Pearson correlation coefficients for assessment of interchip variability
Sample ID
JS020
JS052
JS079

R
0.998
0.998
0.997

p-value
<0.0001
<0.0001
<0.0001
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Table A.4 Distribution of the beta values for the CpG sites assessed in manuscript 1
Gene

Mean

CYP1A1, CpG site 1
CYP1A1, CpG site 2
CYP1A1, CpG site 3
CYP1A1, CpG site 4
HIF1A, CpG site 1
HIF1A, CpG site 2
GSTM1
GSTT1

0.02
0.05
0.04
0.19
0.04
0.03
0.10
0.09

Standard
Deviation
0.01
0.01
0.03
0.03
0.01
0.02
0.10
0.11

Minimum

Maximum

0.01
0.03
0.01
0.13
0.02
0.01
0.01
0.02

0.04
0.08
0.14
0.25
0.10
0.17
0.35
0.45
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Table A.5 Summary of the confounders assessed for the association between SGA1 and methylation of selected genes
CYP1A1

Variable

Variable
type

crude association

1

OR2,3

HIF1A

%
Change4

0.868

OR

GSTM1
%
change

1.232

OR

GSTT1

% change

0.972

OR

%
change

1.077

Gender

categorical

0.985

13.48

1.428

15.91

0.984

1.23

1.087

0.93

Parity

categorical

0.894

3.00

1.206

-2.11

0.964

-0.82

1.091

1.30

Smoker
Smoke exposure (cotinine
level)

categorical

0.836

-3.69

1.247

1.22

0.973

0.10

1.076

-0.09

continuous

0.814

-6.22

1.241

0.73

0.976

0.41

1.069

-0.74

Prenatal vitamin use

categorical

0.870

0.23

1.241

0.73

0.972

0.00

1.079

0.19

Pregnancy complications

categorical

0.893

2.88

1.223

-0.73

0.973

0.10

1.077

0.00

Maternal age

continuous

0.889

2.42

1.231

-0.08

0.975

0.31

1.102

2.32

Prenatal care

categorical

0.877

1.04

1.184

-3.90

0.980

0.82

1.086

0.84

Race-white, black, other

categorical

0.873

0.58

1.213

-1.54

0.992

2.06

1.071

-0.56

Race-black, non-black

categorical

0.868

0.00

1.219

-1.06

0.994

2.26

1.073

-0.37

SGA=small for gestational age

2

OR=Odds ratio

3

Odds ratios for a 0.01 increase in methylation level

4

the percent change in the odds ratio from the crude odds ratio attributed to the addition of the selected variable
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Table A.6 Parameter estimates and model fit statistics for the crude and adjusted models assessing the association between
methylation of selected genes and SGA
Hosmer and
Lemeshow
Goodness-of-fit test
Variable

Parameter
Estimate

Standard
Error

Wald
Chi-Square

pr>
Chi-square

Intercept
CYP1A1

-1.03
-14.10

2.18
29.43

0.22
0.23

0.64
0.63

Intercept

-0.46

3.63

0.02

0.90

CYP1A1

-3.29

43.96

0.01

0.94

Gender

-3.06

1.31

5.47

0.02

Maternal Age

-0.06

0.09

0.45

0.50

Parity

1.07

0.94

1.30

0.25

Cotinine

0.03

0.02

2.35

0.13

-0.56

0.94

0.35

0.55

2.12

0.97

4.79

0.03

CYP1A1

CYP1A1

Prenatal Care
Race
HIF1A
Intercept

-2.86

0.75

14.48

<0.01

HIF1A

20.85

17.12

1.48

0.22

Model fit statistics
for the intercept and
covariates
AIC
-2 Log L

Chisquare
4.50

p-value
0.81

66.56

62.56

2.43

0.97

55.76

39.76

13.70

0.09

65.46

61.46
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Table A.6 (Continued) Parameter estimates and model fit statistics for the crude and adjusted models assessing the association
between methylation of selected genes and SGA
Hosmer and
Lemeshow
Goodness-of-fit test
Parameter
Estimate

Standard
Error

Intercept
HIF1A
Gender
Maternal Age
Parity
Cotinine
Prenatal Care
Race

-1.22
46.50
-4.02
-0.10
0.99
0.04
-0.44
2.10

2.85
24.18
1.67
0.10
1.01
0.02
0.93
1.00

0.18
3.70
5.83
1.02
0.96
2.67
0.22
4.39

0.67
0.05
0.02
0.31
0.33
0.10
0.64
0.04

Intercept
GSTM1

-1.82
-2.83

0.46
3.78

15.96
0.56

<0.01
0.46

Variable

Wald
Chi-Square

pr>
Chi-square

HIF1A

GSTM1

GSTM1
Intercept
GSTM1
Maternal Age
Parity
Cotinine
Prenatal Care
Race

-1.40
0.48
-0.05
0.97
0.02
-0.97
2.02

2.33
4.24
0.08
0.89
0.02
0.79
0.84

0.36
0.01
0.44
1.19
1.17
1.50
5.73

Model fit statistics
for the intercept and
covariates
AIC
-2 Log L

Chisquare
4.77

p-value
0.78

52.23

36.23

1.99

0.98

66.18

62.18

3.83

0.87

63.63

49.63

0.55
0.91
0.51
0.27
0.28
0.22
0.02
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Table A.6 (Continued) Parameter estimates and model fit statistics for the crude and adjusted models assessing the association
between methylation of selected genes and SGA
Hosmer and
Lemeshow
Goodness-of-fit test
Variable

Parameter
Estimate

Standard
Error

-3.05
7.41

0.55
2.44

Wald
Chi-Square

pr>
Chi-square

GSTT1
Intercept
GSTM1

30.61
9.20

-0.50
9.91
-0.12
1.38
0.00
-1.28
1.64

2.89
3.58
0.10
1.05
0.02
0.92
0.91

0.03
7.66
1.46
1.73
0.02
1.94
3.23

Chisquare
15.78

p-value
0.05

57.71

53.71

8.22

0.41

54.34

40.34

<0.01
<0.01

GSTT1
Intercept
GSTM1
Maternal Age
Parity
Cotinine
Prenatal Care
Race

Model fit statistics
for the intercept and
covariates
AIC
-2 Log L

0.86
0.01
0.23
0.19
0.88
0.16
0.07
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Table A.7 Summary of the confounders assessed for the association between methylation of selected genes and cigarette smoke
exposure
GSTT1

Variable

variable
type

crude
Gender

1

OR1,2

GSTM1

%
change3

1.030
categorical

1.031

HIF1A

%
change

OR
0.985

0.10

0.984

OR

CYP1A1

%
change

1.010
-0.10

1.011

OR

%
change

0.998
0.10

0.997

-0.10

Parity

categorical

1.030

0.00

0.984

-0.10

1.011

0.10

1.000

0.20

Prenatal vitamin use

categorical

1.029

-0.10

0.982

-0.30

1.007

-0.30

0.995

-0.30

Pregnancy complications

categorical

1.030

0.00

0.985

0.00

1.011

0.10

0.998

0.00

Maternal age

continuous

1.031

0.10

0.989

0.41

1.015

0.50

0.999

0.10

prenatal care

categorical

1.032

0.19

0.986

0.10

1.011

0.10

0.998

0.00

Race-white, black, other

categorical

1.032

0.19

0.983

-0.20

1.005

-0.50

0.992

-0.60

Race-black, non-black

categorical

1.031

0.10

0.986

0.10

1.011

0.10

0.998

0.00

Gestational age

continuous

1.032

0.19

0.987

0.20

1.010

0.00

0.997

-0.10

OR=odds ratio

2

The odds ratio is for a 1 ng/ml increase in cotinine level

3

the percent change in the odds ratio from the crude odds ratio attributed to the addition of the selected variable
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Table A.8 Parameter estimates and model fit statistics for the crude and adjusted models assessing the association between
smoking and hypermethylation of selected genes

Variable

Parameter
Estimate

Standard
Error

Wald
Chi-Square

pr>
Chi-square

Hypermethylation
of CYP1A1
Intercept
Cotinine

-1.12
-0.002

0.25
0.02

19.41
0.02

-1.28
0.00
0.01
-0.37

1.22
0.02
0.04
0.64

1.11
0.01
0.04
0.34

-1.12
0.01

0.25
0.01

19.55
0.60

-3.15
0.02
0.07
0.46

1.29
0.01
0.04
0.60

5.93
1.23
2.58
0.61

-2 Log L

3.13

0.08

104.09

100.09

7.78

0.46

107.60

99.60

0.08

.

105.73

101.73

8.84

0.26

106.96

98.96

<0.01
0.44

Hypermethylation
of HIF1A
Intercept
Cotinine
Maternal Age
Race

AIC

0.29
0.94
0.83
0.56

Hypermethylation
of HIF1A
Intercept
Cotinine

Model fit statistics
for the intercept
and covariates

<0.01
0.89

Hypermethylation
of CYP1A1
Intercept
Cotinine
Maternal Age
Race

Hosmer and
Lemeshow
Goodness-of-fit
test
Chisquare
p-value

0.01
0.27
0.11
0.44
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Table A.8 (Continued) Parameter estimates and model fit statistics for the crude and adjusted models assessing the association
between smoking and hypermethylation of selected genes

Variable

Parameter
Estimate

Standard
Error

Wald
Chi-Square

pr>
Chi-square

Hypermethylation
of GSTM1
Intercept
Cotinine

-1.02
-0.01

0.25
0.02

16.77
0.52

-1.98
-0.01
0.04
-0.74

1.22
0.02
0.04
0.70

2.64
0.31
0.93
1.11

-1.23
0.03

0.26
0.02

22.17
3.89

-2.72
0.03
0.04
1.29

1.35
0.02
0.04
0.59

4.02
4.67
0.82
4.77

-2 Log L

0.90

0.34

105.65

101.65

8.81

0.29

106.75

98.75

0.01

.

101.78

97.78

10.20

0.18

100.88

92.88

<0.01
0.05

Hypermethylation
of GSTT1
Intercept
Cotinine
Maternal Age
Race

AIC

0.10
0.58
0.34
0.29

Hypermethylation
of GSTT1
Intercept
Cotinine

Model fit statistics
for the intercept
and covariates

<0.01
0.47

Hypermethylation
of GSTM1
Intercept
Cotinine
Maternal Age
Race

Hosmer and
Lemeshow
Goodness-of-fit
test
Chisquare
p-value

0.05
0.03
0.37
0.03
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Table A.9 Summary of the confounders assessed for the association between methylation of IGF1 and IGF2 and birthweight
IGF1
Variable

Variable type

Crude

1

β

1

IGF2
p-value

2

-0.041

β

p-value

-0.006

0.81

Gender

categorical

-0.049

<0.01

-0.019

<0.01

Parity

categorical

-0.043

<0.01

-0.004

<0.01

Smoker

categorical

-0.041

0.54

-0.006

0.58

Smoke exposure (cotinine level)

continuous

-0.041

0.37

-0.004

0.39

Prenatal vitamin use

categorical

-0.040

0.89

-0.006

0.79

Pregnancy complications

categorical

-0.041

0.02

-0.008

0.03

Maternal age

continuous

-0.045

0.01

-0.009

0.02

Gestational age

continuous

-0.029

<0.01

0.007

<0.01

Preterm

categorical

-0.032

<0.01

-0.415

<0.01

Prenatal care

categorical

-0.038

0.17

-0.006

0.14

Race-white, black, other

categorical

-0.039

0.59, 0.70

-0.005

0.46, 0.79

Race-black, non-black

categorical

-0.038

0.70

-0.006

0.47

Betas (β) are for the association of interest and represent the change in log(birthweight) for a one standard deviation increase in

methylation
2

p-value represents the significance of the covariate added to the univariate model
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Table A.10 Summary of the parameter estimates and fit statistics for the crude and
adjusted models examining the association between methylation of IGF1, IGF2, and the
CpG sites in IGF2 and birthweight

Variable

Parameter
Estimate

Standard
Error

8.059
-0.041

t-value

pr>|t|

0.025

318.200

<0.0001

0.025

-1.590

0.115

R sq

IGF1
Intercept
Z-score of
methylation of IGF1

0.028

0.716

IGF1
Intercept
Z-score of
methylation of IGF1

5.044

0.278

18.130

<.0001

-0.036

0.014

-2.530

0.013

Gender

0.088

0.030

2.950

0.004

Maternal Age

0.003

0.002

1.430

0.158

-0.084

0.032

-2.600

0.011

Gestational Age

0.076

0.007

10.540

<.0001

Complications

0.008

0.033

0.230

0.820

Parity

0.001

IGF2
Intercept
Z-score of
methylation of IGF2

8.059

0.026

313.830

<.0001

-0.006

0.026

-0.240

0.811
0.694

IGF2
Intercept
Z-score of
methylation of IGF2

4.984

0.289

17.240

<.0001

0.001

0.015

0.050

0.964

Gender

0.080

0.031

2.580

0.012

Maternal Age

0.003

0.002

1.190

0.239

-0.083

0.033

-2.470

0.016

Gestational Age

0.078

0.007

10.410

<.0001

Complications

0.012

0.034

0.340

0.738

Parity

0.0002

IGF2, CpG site 1
Intercept
Z-score of
methylation of IGF2,
CpG site 1

8.059

0.026

313.750

<.0001

-0.003

0.026

0.905

-0.054
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Table A.10 (Continued) Summary of the parameter estimates and fit statistics for the
crude and adjusted models examining the association between methylation of IGF1,
IGF2, and the CpG sites in IGF2 and birthweight

Variable

Parameter
Estimate

Standard
Error

t-value

pr>|t|

0.694

IGF2, CpG site 1
Intercept
Z-score of
methylation of IGF2,
CpG site 1

4.984

0.288

17.310

<.0001

-0.001

0.015

-0.080

0.940

Gender

0.081

0.031

2.620

0.010

Maternal Age

0.003

0.002

1.190

0.236

-0.083

0.034

-2.470

0.016

Gestational Age

0.078

0.007

10.480

<.0001

Complications

0.012

0.035

0.340

0.735

Parity

0.0001

IGF2, CpG site 2
Intercept
Z-score of
methylation of IGF2,
CpG site 2

8.059

0.026

313.740

<0.0001

-0.002

0.026

-0.090

0.928
0.694

IGF2, CpG site 2
Intercept
Z-score of
methylation of IGF2,
CpG site 2

4.982

0.290

17.210

<.0001

0.001

0.015

0.100

0.922

Gender

0.080

0.031

2.570

0.012

Maternal Age

0.003

0.002

1.190

0.238

-0.083

0.033

-2.470

0.015

Gestational Age

0.078

0.007

10.410

<.0001

Complications

0.012

0.035

0.340

0.733

Parity

0.044

IGF2, CpG site 3
Intercept
Z-score of
methylation of IGF2,
CpG site 3

R sq

8.059

0.025

320.900

<.0001

-0.051

0.025

-2.020

0.047

99

APPENDIX A (CONTINUED)
Table A.10 (Continued) Summary of the parameter estimates and fit statistics for the
crude and adjusted models examining the association between methylation of IGF1,
IGF2, and the CpG sites in IGF2 and birthweight

Variable

Parameter
Estimate

Standard
Error

t-value

pr>|t|

0.699

IGF2, CpG site 3
Intercept
Z-score of
methylation of IGF2,
CpG site 3

5.037

0.288

17.460

<.0001

-0.018

0.015

-1.210

0.228

Gender

0.083

0.031

2.730

0.008

Maternal Age

0.003

0.002

1.190

0.238

-0.077

0.033

-2.310

0.024

Gestational Age

0.076

0.007

10.260

<.0001

Complications

0.008

0.034

0.240

0.807

Parity

0.001

IGF2, CpG site 4
Intercept
Z-score of
methylation of IGF2,
CpG site 4

8.059

0.026

313.810

<.0001

-0.005

0.026

-0.210

0.835
0.699

IGF2, CpG site 4
Intercept
Z-score of
methylation of IGF2,
CpG site 4

4.982

0.285

17.450

<.0001

-0.017

0.015

-1.150

0.252

Gender

0.079

0.031

2.580

0.012

Maternal Age

0.003

0.002

1.340

0.183

-0.086

0.033

-2.580

0.012

Gestational Age

0.078

0.007

10.540

<.0001

Complications

0.009

0.034

0.260

0.795

Parity

0.0003

IGF2, CpG site 5
Intercept
Z-score of
methylation of IGF2,
CpG site 5

R sq

8.059

0.026

313.770

<.0001

0.004

0.026

0.150

0.880
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Table A.10 (Continued) Summary of the parameter estimates and fit statistics for the
crude and adjusted models examining the association between methylation of IGF1,
IGF2, and the CpG sites in IGF2 and birthweight

Variable

Parameter
Estimate

Standard
Error

t-value

pr>|t|

0.697

IGF2, CpG site 5
Intercept
Z-score of
methylation of IGF2,
CpG site 5

4.962

0.288

17.230

<.0001

0.012

0.015

0.840

0.406

Gender

0.077

0.031

2.470

0.016

Maternal Age

0.003

0.002

1.230

0.224

-0.084

0.033

-2.520

0.014

Gestational Age

0.078

0.007

10.550

<.0001

Complications

0.014

0.034

0.400

0.691

Parity

R sq
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Table A.11 Association between birthweight and DNA methylation of IGF1, IGF2, and
the CpG sites in IGF2 after adding race as a covariate
Β1, 2
95% CI3
IGF1
-3.12
-6.09, -0.15
IGF2
0.26
-2.69, 3.21
CpG site 1
-0.04
-2.98, 2.89
CpG site 2
0.16
-2.79, 3.11
CpG site 3
-1.45
-4.44, 1.53
CpG site 4
-1.88
-4.79, 1.03
CpG site 5
1.62
-1.33, 4.56
1
Percent change in birthweight per standard deviation change in methylation level
2

Adjusted for gender, maternal age, parity, gestational age, pregnancy complications,

and race
3

CI=confidence interval
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Birthweight versus z-score transformed
methylation levels of the IGF2 gene
6000

birthweight (grams)

5000
4000
3000
2000
1000
0
-4

-3

-2

-1

0

1

2

3

4

z-score
Figure A.1 Plot of birthweight verses the z-score transformed methylation values for the
IGF2 gene
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Birthweight versus z-score transformed
methylation levels of the IGF1 gene
6000

birthweight (grams)

5000
4000
3000
2000
1000
0
-4

-3

-2

-1

0

1

2

3

4

z-score
Figure A.2 Plot of birthweight verses the z-score transformed methylation values for the
IGF1 gene

104

APPENDIX B: DATA COLLECTION FORM

105

106

APPENDIX C: POWER ANALYSIS
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For manuscript 1, the logistic statement in proc power (SAS 9.2) was used to
perform the power analysis. For the analyses examining the association between SGA
and DNA methylation of CYP1A1, HIF1a, GSTM1, or GSTT1, the distribution of the
predictor of interest, DNA methylation, was specified for each gene, alpha was kept at
0.05, and the sample size was fixed at 90. Power was calculated for several different
odds ratios (1.1, 1.5, 2.0, and 2.5) using a response probability of 0.11. Table C.1
provides an overview of the results from the power calculations. GSTT1 and GSTM1 had
greater than 80% power for all the odds ratios examined. The study was underpowered
to detect small changes in the odds ratio for CYP1A1 and HIF1A, but had greater than
90% power for larger odds ratios (i.e. odds ratios of 2.5). Manuscript one also sought to
examine the association between cotinine level and DNA hypermethylation (outcome).
For this power analysis, alpha was set at 0.05, response probability was 0.25, the
sample size was fixed at 90, and the distribution of the cotinine variable was specified.
Power was the same for all the genes (>99%) and is summarized in Table C.1.
For manuscript 2, the power analysis was done using the multreg statement in
proc power (SAS 9.2). Alpha was fixed at 0.05, the sample size was 90 and the Rsquare of the full model as well as the change in R-square were specified for both IGF1
and IGF2. While there was sufficient power for IGF1 (86.6%), analyses of IGF2 lacked
power (7.3%).
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APPENDIX C (CONTINUED)
Table C.1. Summary of power analysis for Manuscript 1
SGA and methylation of each gene
CYP1A1
HIF1A
GSTM1
GSTT1
Hypermethylation of each gene and
cotinine level

Power
OR=1.1
6.2%
6.8%
81.0%
88.3%
>99.9%

OR=1.5
28.3%
41.7%
>99.9%
>99.9%
>99.9%

OR=2.0
68.7%
87.7%
>99.9%
>99.9%
>99.9%

OR=2.5
91.3%
98.8%
>99.9%
>99.9%
>99.9%
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